US5484773A - Treatment of antibiotic associated diarrhea - Google Patents

Treatment of antibiotic associated diarrhea Download PDF

Info

Publication number
US5484773A
US5484773A US08/195,009 US19500994A US5484773A US 5484773 A US5484773 A US 5484773A US 19500994 A US19500994 A US 19500994A US 5484773 A US5484773 A US 5484773A
Authority
US
United States
Prior art keywords
toxin
oligosaccharide
composition
group
oligosaccharide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/195,009
Inventor
Louis D. Heerze
Glen D. Armstrong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synsorb Biotech Inc
Ilypsa Inc
Original Assignee
Alberta Innovates
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alberta Innovates filed Critical Alberta Innovates
Priority to US08/195,009 priority Critical patent/US5484773A/en
Assigned to ALBERTA RESEARCH COUNCIL reassignment ALBERTA RESEARCH COUNCIL ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ARMSTRONG, GLEN D., HEERZE, LOUIS D.
Priority to IL11242895A priority patent/IL112428A/en
Priority to ZA95630A priority patent/ZA95630B/en
Priority to CN95191615A priority patent/CN1131070C/en
Priority to PCT/CA1995/000060 priority patent/WO1995021628A1/en
Priority to CA002181359A priority patent/CA2181359C/en
Priority to DE69533084T priority patent/DE69533084T2/en
Priority to JP52086995A priority patent/JP4122052B2/en
Priority to NZ328329A priority patent/NZ328329A/en
Priority to AT95907526T priority patent/ATE267614T1/en
Priority to NZ279180A priority patent/NZ279180A/en
Priority to EP95907526A priority patent/EP0744959B1/en
Priority to AU15727/95A priority patent/AU698275B2/en
Priority to US08/450,572 priority patent/US5635606A/en
Assigned to SYNSORB BIOTECH INC. reassignment SYNSORB BIOTECH INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALBERTA RESEARCH COUNCIL
Publication of US5484773A publication Critical patent/US5484773A/en
Application granted granted Critical
Priority to MX9603403A priority patent/MX197129B/en
Priority to NO963378A priority patent/NO963378D0/en
Priority to KR19967004399A priority patent/KR970701064A/en
Assigned to GATX/MM VENTURE FINANCE PARTNERSHIP reassignment GATX/MM VENTURE FINANCE PARTNERSHIP SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SYNSORB BIOTECH, INC.
Assigned to ILYPSA, INC. reassignment ILYPSA, INC. CONFIRMATORY PATENT ASSIGNMENT AGREEMENT Assignors: ITERATION ENERGY, LTD.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals

Definitions

  • This invention relates to treatment of antibiotic associated diarrhea, including Clostridium difficile associated diarrhea (CDAD) and pseudomembranous colitis (PMC). More specifically, the invention concerns neutralization of C. difficile toxin A associated with CDAD.
  • CDAD Clostridium difficile associated diarrhea
  • PMC pseudomembranous colitis
  • Clostridium difficile is the major causative agent of antibiotic-associated bacterial diarrhea and pseudomembranous colitis (PMC) among mainly elderly patients in hospitals and long term care facilities [1,2].
  • PMC pseudomembranous colitis
  • the organism cannot compete successfully with the normal microbial flora in the adult colon, but when the normal intestinal microflora is altered, for example by antibiotic treatment, C. difficile is able to colonize the gut in high numbers.
  • Antibiotic therapy accounts for 98% of all cases of C. difficile associated diarrhea (CDAD).
  • CDAD C. difficile associated diarrhea
  • any predisposing condition which alters the normal intestinal flora including any condition which requires extensive immunosuppressive treatment, can also lead to the development of CDAD.
  • AIDS patients are also high risk candidates for acquiring CDAD [3,4].
  • C. difficile produces two exotoxins, toxin A (an enterotoxin) and toxin B (a cytotoxin) which appear to play important roles in causing CDAD.
  • Toxin A is primarily responsible for the disease. It acts by binding to epithelial cells in the intestine, resulting in the destruction of these cells and causing the secretion of fluid into the intestine. The destruction of these protective epithelial cells by toxin A represents the crucial step leading to the development of diarrhea. Once damage has occurred to the epithelial cells, the potent cytotoxin B can then gain access to underlying sensitive tissues and initiate additional clinical symptoms.
  • Toxin A has been found to display a lectin-like activity which allows it to bind to an oligosaccharide receptor on epithelial cells.
  • oligosaccharide sequences have been identified as potential receptors for toxin A, and include the following structures [5-7]:
  • toxin A preparations have been obtained using bovine thyroglobulin affinity columns which have terminal ⁇ Gal(1-3) ⁇ Gal(1-4) ⁇ GlcNAc oligosaccharide sequences [8,9].
  • the current therapy for patients who suffer from CDAD or PMC is to remove the offending drug and begin oral administration of the antibiotics Metronidazole or Vancomycin along with fluid replacement [3,14]. Vancomycin is only used in certain situations when patients cannot tolerate or are not responsive to Metronidazole treatment. In addition, Vancomycin is not used routinely because of its high cost. This form of therapy is effective in about 80% of the patients who suffer from CDAD or PMC. In about 20% of patients, the diarrhea returns after discontinuing antibiotic treatment [15]. In such individuals, episodes continue to recur until the normal intestinal flora is reestablished and the numbers of C. difficile organisms are reduced. This is a slow process, since antibiotics such as Metronidazole, which disturb the balance of the normal intestinal flora, are administered each time the diarrhea occurs.
  • one method for detecting C. difficile in a sample is to culture the sample.
  • the disadvantages of this method include the length of time required and interference by non-pathogenic, i.e. non-toxin producing, C. difficile strains.
  • Other methods involve the use of specific antisera or monoclonal antibodies.
  • U.S. Pat. Nos. 4,863,852 and 5,098,826 describe methods for detecting C. difficile toxin A by the use of reagents containing biological receptors for toxin A, including the ⁇ Gal(1-3) ⁇ Gal(1-4) ⁇ GlcNAc, X and Y antigen oligosaccharide sequences, bound to a support.
  • a preferred compound which would treat antibiotic associated diarrhea.
  • a preferred compound would be administered noninvasively, such as orally.
  • the invention provides compositions and methods for the treatment of antibiotic associated diarrhea caused by Clostridium difficile.
  • the invention provides a method to bind and remove toxin A from a sample suspected of containing said toxin A, which method comprises contacting said sample with an oligosaccharide sequence covalently attached to a solid, inert support through a non-peptidyl compatible linker arm, wherein said oligosaccharide sequence binds toxin A, under conditions wherein said toxin A is absorbed to said support; and separating the support containing the absorbed toxin A from the sample.
  • the invention provides a method to treat diarrhea mediated by toxin A in a subject, which method comprises administering to a subject in need of such treatment an effective amount of a composition comprising an oligosaccharide sequence covalently attached to a pharmaceutically acceptable solid, inert support through a non-peptidyl compatible linker arm, wherein said oligosaccharide sequence binds toxin A, and wherein said composition is capable of being eliminated from the gastrointestinal tract.
  • the invention provides a pharmaceutical composition useful in treating CDAD and related conditions initiated by toxin A, which composition comprises an oligosaccharide sequence covalently attached to a pharmaceutically acceptable solid, inert support through a non-peptidyl compatible linker arm, wherein said oligosaccharide sequence binds toxin A; and a pharmaceutically acceptable carrier, wherein said composition is capable of being eliminated from the gastrointestinal tract.
  • FIG. 1 demonstrates the neutralization of purified toxin A hemagglutination activity using a panel of SYNSORBs containing various oligosaccharide sequences. Several SYNSORBs were found to effectively neutralize toxin A activity.
  • FIG. 2 illustrates the concentration dependent neutralization of toxin A activity using SYNSORB 52 and 90. Both SYNSORBs can effectively neutralize more than about 75% of toxin A activity at a concentration of 20 mg/ml.
  • FIG. 3 demonstrates the time dependency of neutralization of toxin A activity using SYNSORB 52 and 90 at a concentration of 20 mg/ml.
  • FIG. 4 illustrates the binding affinity of several SYNSORBs for toxin A. Different SYNSORBs were found to have different binding affinities for the toxin.
  • Antibiotic-associated bacterial diarrhea refers to the condition wherein antibiotic therapy disturbs the balance of the microbiol flora of the gut, allowing pathogenic organisms such as Clostridium difficile to flourish. These organisms cause diarrhea.
  • Antibiotic-associated bacterial diarrhea includes such conditions as Clostridium difficile associated diarrhea (CDAD) and pseudomembranous colitis (PMC).
  • biocompatible refers to chemical inertness with respect to human tissues or body fluids.
  • compatible linker arm refers to a moiety which serves to space the oligosaccharide structure from the biocompatible solid support and which is biofunctional wherein one functional group is capable of binding to a reciprocal functional group of the support and the other functional group is capable of binding to a reciprocal functional group of the oligosaccharide structure.
  • Compatible linker arms preferred in the present invention are non-peptidyl spacer arms.
  • PMC pseudomembranous colitis
  • enteritis refers to the inflammation of the mucous membrane of both small and large intestine with the formation and passage of pseudomembranous material (composed of fibrin, mucous, necrotic epithelial cells and leukocytes) in the stools.
  • solid support refers to an inert, solid material to which the oligosaccharide sequences may be bound via a compatible linker arm. Where use is in vivo, the solid support will be biocompatible.
  • SYNSORB refers to synthetic 8-methoxycarbonyloctyl oligosaccharide structures covalently coupled to Chromosorb PTM (Manville Corp., Denver, Colo.) (12), which is a derivitized silica particle.
  • toxin A refers to an enterotoxin of Clostridium difficile which initiates CDAD and related conditions. This toxin has a lectin-like activity.
  • the chemical synthesis of all or part of the oligosaccharide glycosides first involves formation of a glycosidic linkage on the anomeric carbon atom of the reducing sugar or monosaccharide.
  • an appropriately protected form of a naturally occurring or of a chemically modified saccharide structure (the glycosyl donor) is selectively modified at the anomeric center of the reducing unit so as to introduce a leaving group comprising halides, trichloroacetimidate, acetyl, thioglycoside, etc.
  • the donor is then reacted under catalytic conditions well known in the art with an aglycon or an appropriate form of a carbohydrate acceptor which possesses one free hydroxyl group at the position where the glycosidic linkage is to be established.
  • aglycon moieties are known in the art and can be attached with the proper configuration to the anomeric center of the reducing unit.
  • the saccharide glycoside can be used to effect coupling of additional saccharide unit(s) or chemically modified at selected positions or, after conventional deprotection, used in an enzymatic synthesis.
  • chemical coupling of a naturally occurring or chemically modified saccharide unit to the saccharide glycoside is accomplished by employing established chemistry well documented in the literature [21-37].
  • the solid supports to which the oligosaccharide structures of the present invention are bound may be in the form of sheets or particles.
  • a large variety of biocompatible solid support materials are known in the art. Examples thereof are silica, synthetic silicates such as porous glass, biogenic silicates such as diatomaceous earth, silicate-containing minerals such as kaolinite, and synthetic polymers such as polystyrene, polypropylene, and polysaccharides.
  • the solid supports have a particle size of from about 10 to 500 microns for in vivo use. In particular, particle sizes of 100 to 200 microns are preferred.
  • the oligosaccharide structure(s) is covalently bound or noncovalently (passively) adsorbed onto the solid support.
  • the covalent bonding may be via reaction between functional groups on the support and the compatible linker arm of the oligosaccharide structure. It has unexpectedly been found that attachment of the oligosaccharide structure to the biocompatible solid support through a compatible linking arm provides a product which, notwithstanding the solid support, effectively removes toxin.
  • Linking moieties that are used in indirect bonding are preferably organic biofunctional molecules of appropriate length (at least one carbon atom) which serve simply to distance the oligosaccharide structure from the surface of the solid support.
  • compositions of this invention are preferably represented by the formula:
  • OLIGOSACCHARIDE represents an oligosaccharide group of at least 2 sugar units which group binds to toxin A
  • Y is oxygen, sulfur or nitrogen
  • R is an aglycon linking arm of at least 1 carbon atom
  • SOLID SUPPORT is as defined above
  • n is an integer greater than or equal to 1. Oligosaccharide sequences containing about 2 to 10 saccharide units may be used. Sequences with about 3 to 5 saccharide units are preferred.
  • linking arms are known in the art.
  • a linking arm comprising a para-nitrophenyl group (i.e., --OC 6 H 4 pNO 2 ) has been disclosed [38].
  • the nitro group is reduced to an amino group which can be protected as N-trifluoroacetamido.
  • the trifluoroacetamido group is removed thereby unmasking the amino group.
  • linking arm containing sulfur has been disclosed [39]. Specifically, the linking arm is derived from a 2-bromoethyl group which, in a substitution reaction with thionucleophiles, has been shown to lead to linking arms possessing a variety of terminal functional groups such as --OCH 2 CH 2 SCH 2 CO 2 CH 3 and --OCH 2 CH 2 SC 6 H 4 --pNH 2 . These terminal functional groups permit reaction to complementary functional groups on the solid support, thereby forming a covalent linkage to the solid support. Such reactions are well known in the art.
  • a 6-trifluoroacetamido-hexyl linking arm (--O--(CH 2 ) 6 --NHCOCF 3 ) has been disclosed [40] in which the trifluoroacetamido protecting group can be removed, unmasking the primary amino group used for coupling.
  • linking arms include the 7-methoxycarbonyl-3,6,dioxaheptyl linking arm [41] (--OCH 2 --CH 2 ) 2 OCH 2 CO 2 CH 3 ); the 2-(4-methoxycarbonylbutancarboxamido)ethyl [42] (--OCH 2 CH 2 NHC(O)(CH 2 ) 4 CO 2 CH 3 ); the allyl linking arm [43] (--OCH 2 CH ⁇ CH 2 ) which, by radical co-polymerization with an appropriate monomer, leads to co-polymers; other allyl linking arms [44] are known [--O(CH 2 CH 2 O) 2 CH 2 CH ⁇ CH 2 ].
  • allyl linking arms can be derivatized in the presence of 2-aminoethanethiol [45] to provide for a linking arm --OCH 2 CH 2 CH 2 SCH 2 CH 2 NH 2 .
  • Other suitable linking arms have also been disclosed [21-23, 25, 26].
  • the particular linking employed to covalently attach the oligosaccharide group to the solid support is not critical.
  • the aglycon linking arm is a hydrophobic group and most preferably, the aglycon linking arm is a hydrophobic group selected from the group consisting of ##STR1##
  • SYNSORB Chromosorb PTM
  • a biocompatible solid support e.g., Chromosorb PTM
  • SYNSORB is particularly preferred for these compositions because it is non-toxic and resistant to mechanical and chemical deposition.
  • rats a widely accepted model for preclinical studies, since they are predictive of human response
  • SYNSORBs have been found to pass unaffected through the rat gastrointestinal tract. They were found to be eliminated completely and rapidly (99% eliminated in 72 hours) following oral administration.
  • oligosaccharide moieties on SYNSORB is particularly useful for binding toxin A, since the toxin is thought to possess multiple oligosaccharide binding sites [11].
  • Non-peptidyl linking arms are preferred for use as the compatible linking arms of the present invention.
  • glycopeptides are not desirable because glycopeptides contain several, often different, oligosaccharides linked to the same protein. Glycopeptides are also difficult to obtain in large amounts and require expensive and tedious purification.
  • BSA or HSA conjugates is not desirable due to questionable stability in the gastrointestinal tract when given orally.
  • Covalent attachment of an oligosaccharide group containing a toxin A binding unit through a non-peptidyl spacer arm to an inert solid support permits efficient binding and removal of toxin A from a sample to be analyzed for the presence of toxin A or from the intestine of a patient suffering from CDAD.
  • the oligosaccharide is synthesized with this compatible linker arm attached (in non-derivatized form), highly pure compositions may be achieved which can be coupled to various solid supports.
  • compositions comprising one or more oligosaccharide structures which bind toxin A attached to a solid support.
  • compositions When used for oral administration, which is preferred, these compositions may be formulated in a variety of ways. It will preferably be in liquid or semisolid form. Compositions including a liquid pharmaceutically inert carrier such as water may be considered for oral administration. Other pharmaceutically compatible liquids or semisolids, may also be used. The use of such liquids and semisolids is well known to those of skill in the art.
  • compositions which may be mixed with semisolid foods such as applesauce, ice cream or pudding may also be preferred.
  • Formulations such as SYNSORBs, which do not have a disagreeable taste or aftertaste are preferred.
  • a nasogastric tube may also be used to deliver the compositions directly into the stomach.
  • Solid compositions may also be used, and may optionally and conveniently be used in formulations containing a pharmaceutically inert carrier, including conventional solid carriers such as lactose, starch, dextrin or magnesium stearate, which are conveniently presented in tablet or capsule form.
  • a pharmaceutically inert carrier including conventional solid carriers such as lactose, starch, dextrin or magnesium stearate, which are conveniently presented in tablet or capsule form.
  • the SYNSORB itself may also be used without the addition of inert pharmaceutical carriers, particularly for use in capsule form.
  • Doses are selected to provide neutralization and elimination of the toxin A found in the gut of the effected patient.
  • Useful doses are from about 0.25 to 1.25 micromoles of oligosaccharide/kg body weight/day, preferably about 0.5 to 1.0 micromoles of oligosaccharide/kg body weight/day.
  • SYNSORB compositions this means about 0.5 to 1.0 gram SYNSORB/kg body weight/day, which gives a concentration of SYNSORB in the gut of about 20 mg/ml.
  • Administration is expected to be 3 or 4 times daily, for a period of one week or until clinical symptoms are resolved.
  • the dose level and schedule of administration may vary depending on the particular oligosaccharide structure used and such factors as the age and condition of the subject.
  • Optimal time for complete removal of toxin A activity was found to be about 1 hour at 37° C., using a concentration of SYNSORB of 20 mg in 1 ml sample.
  • oligosaccharide-containing compositions of the present invention during a period of up to seven days will be useful in treating CDAD and PMC.
  • formulations may also be considered for other means of administration such as per rectum.
  • the usefulness of these formulations may depend on the particular composition used and the particular subject receiving the treatment.
  • These formulations may contain a liquid carrier that may be oily, aqueous, emulsified or contain certain solvents suitable to the mode of administration.
  • compositions may be formulated in unit dose form, or in multiple or subunit doses.
  • orally administered liquid compositions should preferably contain about 1 micromole oligosaccharide/ml.
  • C. difficile toxin A may be neutralized by certain oligosaccharide sequences which bind the toxin.
  • synthetic oligosaccharides covalently attached to solid supports via non-peptidyl compatible linker arms have been found to neutralize toxin A effectively.
  • SYNSORBs which bind and neutralize toxin A activity.
  • SYNSORBs 8-methoxylcarbonyloctyl
  • oligosaccharide sequences attached to solid supports useful in the present invention are those which bind toxin A.
  • the binding affinity of an oligosaccharide to toxin A is readily detectable by a simple in vitro test, as for example, set forth in Example 4 below.
  • oligosaccharide sequences attached to solid supports which bind toxin A means those compositions which reduce endpoint titers from hemagglutination assays by at least 50%.
  • SLTs are a group of cytoxins which are made up of two parts: an A subunit and a B oligomer.
  • the B oligomer is the binding portion of the toxin that allows it to bind to host cell receptors.
  • the SLT toxins bind to glycolipid receptors containing the ⁇ Gal(1-4) ⁇ Gal determinant.
  • the A subunit has an enzymatic activity (N-glycosidase) that depurinates 28S ribosomal RNA in mammalian cells. This enzymatic activity abolishes the ability of the toxin-infected cell to perform protein synthesis.
  • SLT The site for SLT action is endothelial cells found in the kidneys and mesenteric vasculature, and SLTs may cause damage that can result in renal failure and hemoglobin in the urine. SLTs are the causative agent in the hemolytic-uremic syndrome. SLTs may also be partially involved in the pathogenesis of hemorrhagic colitis (bloody diarrhea).
  • toxin A is an enterotoxin that induces fluid secretion, mucosal damage and intestinal inflammation. It serves as a chemoattractant for human neutrophils. Toxin A is a single protein. It cause activation and results in the release of cytokines in monocytes. These inflammatory effects may play an important role in inducing the colonic inflammation seen in pseudomembranous colitis.
  • Toxin A appears to bind to a glycoprotein receptor, the structure of which has yet to be determined. The mechanism of action is not totally understood, but toxin A is thought to enter cells via receptor-mediated endocytosis and affect the actin cytoskeleton of the cell. The toxin A receptor is thought to be linked to a guanine regulatory protein. Toxin A is the first step in the production of CDAD and PMC.
  • toxin A Previous studies defining the oligosaccharide binding specificity of toxin A have identified several structural requirements for toxin binding [5-7]. Oligosaccharides which terminate in the ⁇ -Gal(1-3) ⁇ Gal sequences attached to the type 2 core ( ⁇ Gal(1-4) ⁇ GlcNAc) have been shown to be important for binding. In addition, toxin A also recognizes oligosaccharides with fucose attached to the 2 hydroxyl of galactose or the 3 hydroxyl of N-acetylglucosamine of the type 2 core.
  • the SYNSORBs chosen for toxin neutralization studies include carbohydrates which incorporate these structural features as well as other oligosaccharides which encompass the type 6 ( ⁇ Gal(1-4) ⁇ Glc) and type 1( ⁇ Gal(1-3) ⁇ GlcNAc) core structures. Additional SYNSORBs selected for binding studies contain oligosaccharide sequences previously shown to bind to toxin A.
  • the amount of toxin A adsorption to SYNSORB was determined by assaying supernatants for reduction of endpoint titers in hemagglutination assays relative to controls without any added SYNSORB. Results are shown in FIG. 1. Those SYNSORBs which possessed the X, Y, and ⁇ Gal(1-3) ⁇ Gal(1-4) ⁇ GlcNAc oligosaccharide sequences (SYNSORBs 51, 52, and 115) were found to effectively remove toxin A activity by 75, 88, and 88%, respectively.
  • SYNSORBs 9 and 90 were as effective at neutralizing toxin A activity.
  • SYNSORBs 2, 5, 104, 105, and 134 neutralized about 50% of toxin A activity.
  • toxin A is directly related to the oligosaccharide sequences attached to the inert support.
  • the results in FIG. 1 show the importance of the ⁇ Gal(1-3) ⁇ Gal linkage for high affinity toxin binding.
  • oligosaccharide sequences which possess a ⁇ (1-4) linkage between galactose and either N-acetylglucosamine (type 2 core) or glucose (type 6) show high affinity toxin binding.
  • toxin A binds oligosaccharide sequences having fucose attached to the 2 hydroxyl of galactose only.
  • FIGS. 1 and 4 show reduction in endpoint titers from hemagglutination assays. Similar results were obtained in tissue culture assays using Chinese Hamster Ovary (CHO) cells. These studies demonstrated that the CHO cells showed a reduction in endpoint dilution relative to controls when SYNSORB was added to purified toxin A preparations.
  • CHO Chinese Hamster Ovary
  • oligosaccharide sequences attached to solid supports via compatible linker arms have been found to have the ability to neutralize toxin A activity. These sequences, and others that also bind toxin A, may be used to treat CDAD and PMC.
  • Optimal time for complete removal of toxin A activity was found to be about 1 hour at 37° C., using a concentration of SYNSORB of 20 mg in 1 ml sample. Since each gram of SYNSORB contains approximately 0.25 to 1.0 micromoles oligosaccharide, the total amount of oligosaccharide to be given in a daily dose would range from 7.5 to 30 micromoles, using a gut volume of four liters.
  • Treatment of CDAD or PMC may be accomplished by oral administration of compositions containing oligosaccharide sequences covalently bound to a solid support via a compatible linker arm (e.g. SYNSORBs).
  • a compatible linker arm e.g. SYNSORBs
  • the SYNSORB has been found to pass through the stomach of rats intact. It then contacts the toxin A in the intestinal tract. Subsequent elimination of the intact SYNSORB with toxin A bound to it results in elimination of toxin A from the patient.
  • Oligosaccharide sequences covalently attached via compatible linker arms to solid support are useful to treat individuals who suffer from multiple episodes of diarrhea.
  • patients Upon initial reoccurrence of diarrhea, patients would be treated with SYNSORB to remove toxin A from the intestine.
  • the removal of toxin A prevents the initial tissue damage to the intestinal lining, which leads to prevention or reduction of diarrhea.
  • No further treatment with antibiotics need be given, allowing the reestablishment of the normal intestinal microflora within the gut.
  • the advantage of such treatment is that it does not affect the recolonization of the intestinal tract by normal microflora. Treatment until discontinuance of diarrhea would allow complete recovery.
  • treatment with oligosaccharide sequences covalently attached via compatible linker arms to solid supports may be used to treat all individuals who suffer from or are prone to develop CDAD or PMC.
  • SYNSORB in combination with antibiotic therapy will be able to reduce the diarrhea more effectively, leading to more rapid recovery.
  • a major aspect of the invention is the rapid efficient binding of physiological concentration of toxin A present in biological samples, thus permitting assay of the presence and/or quantity of toxin A in these samples.
  • the biological sample will be a stool sample.
  • the sample may be extracted and prepared using standard extraction techniques.
  • the sample or extract is then contacted with the toxin-binding oligosaccharide sequences covalently bound to solid supports via a compatible linker arm under conditions where any toxin A in the sample is absorbed.
  • Toxin A may be measured directly on the surface of the oligosaccharide-containing support using any suitable detection system.
  • any suitable detection system for example, radioactive, biotinylated or fluorescently labelled monoclonal or polyclonal antibodies specific for toxin A may be used to determine the amount of toxin A bound to the support.
  • radioactive, biotinylated or fluorescently labelled monoclonal or polyclonal antibodies specific for toxin A may be used to determine the amount of toxin A bound to the support.
  • a wide variety of protocols for detection of formation of specific binding complexes analogous to standard immunoassay techniques is well known in the art.
  • Toxin A was isolated from a toxin producing strain of C. difficile (ATCC 43255, VPI strain 10463) using slight modifications of the method of Sullivan et al. [13].
  • C. difficile was grown in 2.3 liter of brain heart infusion broth (BHIB) in anaerobic jars for 72 hours at 37° C.
  • BHIB brain heart infusion broth
  • the crude culture was centrifuged at 5,000 ⁇ g for 20 minutes to sediment the bacteria.
  • the resulting culture supernatant was carefully removed and solid ammonium sulfate (897 g) was added to make 60% saturation.
  • the culture supernatant was stirred at 4° C. overnight and then centrifuged at 10,000 ⁇ g for 30 minutes.
  • the resulting pellet was dissolved in a minimum amount of buffer A (50 mM sodium phosphate buffer, pH 7.5), dialyzed against 2-4 liter changes of buffer A and concentrated by ultrafiltration using a YM 100 (100,000 molecular weight cutoff) membrane.
  • buffer A 50 mM sodium phosphate buffer, pH 7.5
  • the concentrated toxin-containing solution was loaded onto a DEAE-Sephadex A-25 column (2.5 ⁇ 20 cm) equilibrated with buffer A. After washing the ion exchange resin with buffer A to remove non-adherent protein, the column was developed with a stepwise salt gradient by washing with buffer A containing increasing amounts of NaCl ranging from 0.1 to 0.4M. Toxin A activity was eluted from the column with buffer A containing 0.25M NaCl, while toxin B activity was removed with 0.4M NaCl buffer A.
  • the overall purity and amount of toxin from each fraction was determined by measuring the protein concentration, as well as using a cytotoxic endpoint using Chinese hamster ovary (CHO) cells.
  • the amount of toxin A activity was also determined by measuring the hemagglutination activity using rabbit erythrocytes.
  • the toxin B fraction was devoid of toxin A activity, as determined by the inability of the toxin B-containing fraction to hemagglutinate rabbit erythrocytes.
  • Fresh rabbit erythrocytes were washed once in phosphate buffered saline (PBS) and resuspended at a concentration of 4% (v/v) in cold PBS.
  • Serial 2-fold dilutions (50 ⁇ l) of toxin A-containing solutions were made in cold PBS in U-shaped microtiter wells.
  • An equal volume (50 ⁇ l) of rabbit erythrocytes was then added to each well and the microtiter plate was mixed gently. After incubating the plate for 4 hours at 4° C., the hemagglutination titer was visually assessed.
  • cytotoxic activity of toxin A was measured by the use of Chinese Hamster Ovary (CHO) cells that were maintained in Hams F12 media supplemented with 10% fetal bovine serum in an atmosphere of 5% CO 2 at 37° C.
  • Toxin A samples to be tested were diluted 1:10 in Hams media and filter sterilized through 0.22 micron syringe filters. Samples to be tested were serial 5-fold diluted in media and 100 ⁇ l of each dilution was added to wells with confluent monolayers of CHO cells, then incubated for 24 hours at 37° C. in an atmosphere of 5% CO 2 . Each sample was analyzed in duplicate.
  • a solution containing purified toxin A prepared as described above (0.5 ml) was added to various SYNSORBs containing different oligosaccharide sequences covalently attached to a solid support via an MCO compatible linker arm.
  • the amount of SYNSORB used ranged from 10.1 to 17.5 mg.
  • the samples were prepared in 1.5 ml microcentrifuge tubes which were incubated at room temperature for 2 hours on an end-over-end rotator.
  • SYNSORB SYNSORB
  • MCO hydrophobic 8 carbon
  • Results are shown in FIG. 1, and demonstrate that several oligosaccharide structures were found to effectively neutralize toxin A activity.
  • SYNSORBS 52 and 90 required for maximal toxin A neutralization was determined by adding 1 ml of a purified toxin A solution to pre-weighed amounts of each SYNSORB in 1.5 ml microcentrifuge tubes.
  • SYNSORB 52 samples were tested using 12.8, 21.6 and 43.3 mg amounts of SYNSORB 52;
  • SYNSORB 90 samples were tested using 12.9, 19.2 and 42.3 mg amounts of SYNSORB 90. Samples were incubated for 2 hours at 37° C. on an end-over-end rotator. Control samples containing only toxin A solution were also tested.
  • the amount of neutralization in each sample was determined by comparing the endpoint titers of hemagglutination assays from samples with and without SYNSORB.
  • the results, shown in FIG. 2, demonstrate that about 20 mg of each SYNSORB tested was able to neutralize at least 75% of the toxin A in 1 ml of toxin A solution.
  • the length of incubation time required for optimal neutralization was determined by incubating microcentrifuge tubes containing 1 ml of purified toxin A solution and 20 mg of either SYNSORB 52 or SYNSORB 90. Samples were incubated at 37° C. on an end-over-end rotator for 10, 20, 40, 80 or 160 minutes.
  • the degree of neutralization at each incubation period was determined as described above.
  • the results, shown in FIG. 3, demonstrate that about 1 hour incubation (between 40 and 80 minutes) resulted in effective neutralization of toxin A.
  • Toxin A positive human stool samples were obtained from University of Alberta Hospital's Microbiology Laboratory. One ml of each stool sample was placed in a 1.5 ml microcentrifuge tube, 20 mg SYNSORB 52 (pre-wetted with 50 ⁇ l PBS) was added, and the tubes were incubated on an end-over-end rotator for 4 hours at 37° C. Control stool samples without SYNSORB were also tested simultaneously. After incubation the stool samples were centrifuged at 14,000 rpm in an Eppendorf Microcentrifuge for 10 minutes. The resulting supernatants were carefully removed and placed into clean microcentrifuge tubes.
  • the amount of toxin A in each sample was determined by using the PREMIERTM C. difficile Toxin A detection kit (Meridian Diagnostics, Cincinnati, Ohio). The percent neutralization was assessed by measuring the reduction in the absorbance at 450 nm relative to individual control samples without added SYNSORB.
  • Results demonstrate that SYNSORB 52 was able to neutralize toxin A activity in human biological samples.
  • each SYNSORB was combined with toxin A as described in Example 1. Endpoint titers from hemagglutination assays using rabbit erythocytes were determined as described previously. SYNSORBs that were more effective at neutralizing toxin A activity possessed oligosaccharide structures that bound to toxin A with higher affinities. Those SYNSORBs which reduced titers by greater than 50% were deemed to bind toxin A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates to treatment of antibiotic associated diarrhea, including Clostridium difficile associated diarrhea (CDAD) and pseudomembranous colitis (PMC), using oligosaccharide compositions which bind C. difficile toxin A. More specifically, the invention concerns neutralization of C. difficile toxin A associated with CDAD.

Description

FIELD OF THE INVENTION
This invention relates to treatment of antibiotic associated diarrhea, including Clostridium difficile associated diarrhea (CDAD) and pseudomembranous colitis (PMC). More specifically, the invention concerns neutralization of C. difficile toxin A associated with CDAD.
REFERENCES
The following references are cited in the application as numbers in brackets ([]) at the relevant portion of the application.
1. Bartlett, J G, et al., "Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia", N. Engl. J. Med. 298: 531-534 (1978).
2. Lyerly, D M, "Epidemiology of Clostridium difficile disease", Clin. Microbiol. News 15: 49-53 (1993).
3. Cozart, J C, et al., "Clostridium difficile diarrhea in patients with AIDS versus non-AIDS controls. Method of treatment and clinical response to treatment", J. Clin. Gastroenterol. 16: 192-4 (1993).
4. Barbut, F, et al., "Comparison of enterotoxin production, cytotoxin production, serogrouping and antimicrobial susceptibilities of Clostridium difficile strains isolated from AIDS and human immunodeficiency virus-negative patients", J. Clin. Microbiol. 31: 740-2 (1993).
5. Krivan, H C, et al., "Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence αGal(1-3)βGal(1-4)βGlcNAc", Infect. Immun., 53: 573-81 (1986).
6. Clark, G F, et al., "Toxin A from Clostridium difficile binds to rabbit erythrocyte glycolipids with terminal αGal(1-3)βGal(1-4)βGlcNAc sequences", Arch. Biochem. Biophys., 257: 217-29 (1987).
7. Tucker, K D, et al., "Toxin A of Clostridium difficile binds to carbohydrate antigens I, X, and Y", Infect. Immun., 59: 73-8 (1991).
8. Krivan, H C, et al., "Purification of Clostridium difficile toxin A by affinity chromatography on immobilized bovine thyroglobulin", Infect. Immun., 55: 1873-7 (1987).
9. Kamiya, S, et al., "Analysis of purity of Clostridium difficile toxin A derived by affinity chromatography on immobilized bovine thyroglobulin", FEMS Microbiol. Lett., 56: 331-6 (1988).
10. Armstrong, G D, et al., "Investigation of shiga-like toxin binding to chemically synthesized oligosaccharide sequences", J. Infect. Dis., 164: 1160-7 (1991).
11. Von Eichel-Streiber, C., et al., "Clostridium difficile toxin A carries a c-terminal repetitive structure homologous to the carbohydrate binding region of streptococcal glycosyltransferases", Gene, 96: 107-13 (1990).
12. Lemieux, R U, et al., "The properties of a `synthetic` antigen related to the blood-group Lewis A", J. Am. Chem. Soc., 97: 4076-83 (1975).
13. Sullivan, N M, et al., "Purification and characterization of toxin A and B from Clostridium difficile", Infect. Immun., 35: 1032-40 (1983).
14. Finegold, S M, et al., "Therapy directed against Clostridium difficile and its toxins. Complications of therapy". In Rolfe, R. D. et al. (eds) C. difficile: It's Role in Intestinal Disease, Academic Press, Inc., San Diego, Calif. 341-57 (1988).
15. Bartlett, J G, et al., "Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis", Gastroenterology, 78: 431-4 (1989).
16. Tedesco, F J, "Pseudomembranous colitis: Pathogenesis and therapy", Med. Clin. North Am., 66: 655-64 (1982).
17. Keighley, M R B, "Antibiotic-associated pseudomembranous colitis: pathogenesis and management", Drugs, 20: 449-56 (1980).
18. Bartlett, J D, "Treatment of antibiotic-associated pseudomembranous colitis", Rev. Infect. Dis., 6, Suppl. 1: 1-55 (1984).
19. Onderdonk, A B, et al., "Comparative effects of clindamycin and clindamycin metabolites in the hamster model for antibiotic-associated colitis", J. Antimicrob. Chem., 8: 383-93 (1981).
20. Triadfilopoulos, G, et al., "Differential effects of Clostridium difficile toxin a and b on rabbit ileum", Gastroenterology, 93: 273-9 (1987).
21. Lemieux, R. U., et al., "Glycoside-Ether-Ester Compounds", U.S. Pat. No 4,137,401, issued Jan. 30, 1979.
22. Lemieux, R. U., et al., "Artificial Oligosaccharide Antigenic Determinants", U.S. Pat. No. 4,238,473, issued Dec. 9, 1980.
23. Lemieux, R. U., et al., "Synthesis of 2-Amino-2-Deoxyglycoses and 2-Amino-2-Deoxyglycosides from glycals", U.S. Pat. No. 4,362,720, issued Dec. 7, 1982.
24. Cox, D., et al. "A New Synthesis of 4-O-α-D-Galactopyranosyl-D-Galacto-Pyranose", Carbohy. Res., 62: 245-252 (1978).
25. Dahmen, J., et al., "Synthesis of space arm, lipid, and ethyl glycosides of the trisaccharide portion [α-D-Gal-(1-4)-β-D-Gal(1-4)-β-D-Glc] of the blood group pk antigen: preparation of neoglycoproteins", Carbohydrate Research, 127: 15-25 (1984).
26. Garegg, P. J., et al., "A Synthesis of 8-Methoxycarbonyloct-1-yl O-α-D-Galactopyranosyl-(1→3)-0-β-D-Galactopyranosyl-(1.fwdarw.4)-2-Acetamido-2-Deoxy-β-D-Glucopyranoside", Carbohy. Res., 136: 207-213 (1985).
27. Garegg, P. J., et al., "Synthesis of 6- and 6'-deoxy derivatives of methyl 4-0-α-D-galactopyranosyl-β-D-galactopyranoside for studies of inhibition of pyelonephritogenic fimbriated E. coli adhesion to urinary epithelium-cell surfaces⃡, Carbohy. Res., 137: 270-275 (1985).
28. Jacquinet, J. C., et al., "Synthesis of Blood-group Substances, Part 11. Synthesis of the Trisaccharide O-α-D-Galactopyranosyl-(1→3)-O-β-D-galactopyranosyl-(1.fwdarw.4)-2-acetamido-2-deoxy-D-glucopyranose", J. C. S. Perkin, I: 326-330 (1981).
29. Koike, K., et al., "Total Synthesis of Globotriaosyl-E and Z-Ceramides and Isoglobotriaosyl-E-Ceramide," Carbohydr. Res., 163: 189-208 (1987).
30. Schaubach, R., et al., "Tumor-Associated Antigen Synthesis: Synthesis of the Gal-α-(1→3)-Gal-β-(1→4)-GlCNAc Epitope. A specific Determinant for Metastatic Progression?," Liebigs Ann. Chem., 607-614 (1991).
31. Ratcliffe, R. M., et al., "Sialic Acid Glycosides, Antigens, Immunoadsorbents, and Methods for Their Preparation", U.S. Pat. No. 5,079,353, issued Jan. 7, 1992.
32. Okamoto, K., et al., "Glycosidation of Sialic Acid," Tetrahedron, 47: 5835-5857 (1990).
33. Abbas, S. A., et al., "Tumor-Associated Oligosaccharides I: Synthesis of Sialyl-Lewisa Antigenic Determinant", Sialic Acids, Proc. Japan-German Symp. Berlin 22-23 (1988).
34. Paulsen, "Advances in Selective Chemical Syntheses of Complex Oligosaccharides", Angew. Chem. Int. Ed. Eng., 21: 155-173 (1982).
35. Schmidt, "New Methods for the Synthesis of Glycosides and Oligosaccharides--Are There Alternatives to the Koenigs-Knorr Method?" Angew. Chem. Int. Ed. Eng., 25: 212-235 (1986).
36. Fugedi, P., et al., "Thioglycosides as Glycosylating Agents in Oligosaccharide Synthesis", Glycoconjugate J., 4: 97-108 (1987).
37. Kameyama, A., et al., "Total synthesis of sialyl Lewis X", Carbohydrate Res., 209: c1-c4 (1991).
38. Ekborg, G., et al., "Synthesis of Three Disaccharides for the Preparation of Immunogens bearing Immunodeterminants Known to Occur on Glycoproteins", Carbohydrate Research, 110: 55-67 (1982).
39. Dahmen, J., et al., "2-Bromoethyl glycosides: applications in the synthesis of spacer-arm glycosides," Carbohydrate Research, 118: 292-301 (1983).
40. Rana, S. S., et al., "Synthesis of Phenyl 2-Acetamido-2-Deoxy-3-O-α L-Fucopyranosyl-β-D-Glucopyranoside and Related Compounds", Carbohydrate Research, 91: 149-157 (1981).
41. Amvam-Zollo, P., et al. , "Streptococcus pneumoniae Type XIV Polysaccharide: Synthesis of a Repeating Branched Tetrasaccharide with Dioxa-Type Spacer-Arms", Carbohydrate Research, 150: 199-212 (1986).
42. Paulsen, H., "Synthese von oligosaccharid-determinanten mit amid-spacer vom typ des T-antigens", Carbohydr. Res., 104: 195-219 (1982).
43. Chernyak, A. Y., et al., "A New Type of Carbohydrate-Containing Synthetic Antigen: Synthesis of Carbohydrate-Containing Polyacrylamide Copolymers having the Specificity of 0:3 and 0:4 Factors of Salmonella", Carbohydrate Research, 128: 269-282 (1984).
44. Fernandez-Santana, V., et al., "Glycosides of Monoallyl Diethylene Glycol. A New type of Spacer group for Synthetic Oligosaccharides", J. Carbohydrate Chemistry, 8(3), 531-537 (1989).
45. Lee, R. T., et al., "Synthesis of 3-(2-Aminoethylthio) PropylGlycosides", Carbohydrate Research, 37: 193-201 (1974).
The disclosure of the above publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if the language of each individual publication, patent and patent application were specifically and individually included herein.
BACKGROUND OF THE INVENTION
The anaerobic organism Clostridium difficile is the major causative agent of antibiotic-associated bacterial diarrhea and pseudomembranous colitis (PMC) among mainly elderly patients in hospitals and long term care facilities [1,2]. The organism cannot compete successfully with the normal microbial flora in the adult colon, but when the normal intestinal microflora is altered, for example by antibiotic treatment, C. difficile is able to colonize the gut in high numbers. Antibiotic therapy accounts for 98% of all cases of C. difficile associated diarrhea (CDAD). However, any predisposing condition which alters the normal intestinal flora, including any condition which requires extensive immunosuppressive treatment, can also lead to the development of CDAD. For example, recent evidence suggests that AIDS patients are also high risk candidates for acquiring CDAD [3,4].
C. difficile produces two exotoxins, toxin A (an enterotoxin) and toxin B (a cytotoxin) which appear to play important roles in causing CDAD. Toxin A is primarily responsible for the disease. It acts by binding to epithelial cells in the intestine, resulting in the destruction of these cells and causing the secretion of fluid into the intestine. The destruction of these protective epithelial cells by toxin A represents the crucial step leading to the development of diarrhea. Once damage has occurred to the epithelial cells, the potent cytotoxin B can then gain access to underlying sensitive tissues and initiate additional clinical symptoms.
Toxin A has been found to display a lectin-like activity which allows it to bind to an oligosaccharide receptor on epithelial cells. Several oligosaccharide sequences have been identified as potential receptors for toxin A, and include the following structures [5-7]:
______________________________________                                    
αGal(1-3)βGal(1-4)βGlcNac                                 
______________________________________                                    
βGal(1-4)βGlcNAc                                                
                (human blood group antigen X)                             
(1-3)                                                                     
αFuc                                                                
βGal(1-4)βGlcNAc                                                
                (human blood group antigen Y)                             
(1-2)  (1-3)                                                              
αFuc  αFuc                                                    
βGal(1-4)βGlcNac                                                
                (human blood group antigen I)                             
(1-6)                                                                     
βGal                                                                 
(1-3)                                                                     
βGal(1-4)βGlcNAc                                                
______________________________________
In addition, highly purified toxin A preparations have been obtained using bovine thyroglobulin affinity columns which have terminal αGal(1-3)βGal(1-4)βGlcNAc oligosaccharide sequences [8,9].
The current therapy for patients who suffer from CDAD or PMC is to remove the offending drug and begin oral administration of the antibiotics Metronidazole or Vancomycin along with fluid replacement [3,14]. Vancomycin is only used in certain situations when patients cannot tolerate or are not responsive to Metronidazole treatment. In addition, Vancomycin is not used routinely because of its high cost. This form of therapy is effective in about 80% of the patients who suffer from CDAD or PMC. In about 20% of patients, the diarrhea returns after discontinuing antibiotic treatment [15]. In such individuals, episodes continue to recur until the normal intestinal flora is reestablished and the numbers of C. difficile organisms are reduced. This is a slow process, since antibiotics such as Metronidazole, which disturb the balance of the normal intestinal flora, are administered each time the diarrhea occurs.
The only other treatment for CDAD and PMC which removes toxin activity from the intestinal tract involves the use of multigram quantities of anion exchange resins such as cholestyramine and colestipol given orally in combination with antibiotics. This approach has been used to treat mild to moderately ill patients, as well as individuals who suffer from multiple episodes of diarrhea [16,17]. This form of therapy has achieved only moderate success in treatment of the disease [18]. In addition to the lack of efficacy of ion exchange resins, there are several other disadvantages associated with the use of resins. Ion exchange resins do not bind specifically to toxin A. Thus, they may bind to antibiotics themselves, resulting in suboptimal levels of antibiotic within the gut. In addition, if patients are receiving other medications that bind to ion exchange resins, there can be reduced drug levels. A further disadvantage of ion exchange resins is the disagreeable taste and aftertaste which are associated with oral administration of these compounds.
With respect to methods of diagnosis of the presence of toxin A in a sample, one method for detecting C. difficile in a sample is to culture the sample. The disadvantages of this method include the length of time required and interference by non-pathogenic, i.e. non-toxin producing, C. difficile strains. Other methods involve the use of specific antisera or monoclonal antibodies. U.S. Pat. Nos. 4,863,852 and 5,098,826 describe methods for detecting C. difficile toxin A by the use of reagents containing biological receptors for toxin A, including the αGal(1-3)βGal(1-4)βGlcNAc, X and Y antigen oligosaccharide sequences, bound to a support.
In view of the above, there is a need for a compound which would treat antibiotic associated diarrhea. A preferred compound would be administered noninvasively, such as orally.
SUMMARY OF THE INVENTION
The invention provides compositions and methods for the treatment of antibiotic associated diarrhea caused by Clostridium difficile.
In one aspect, the invention provides a method to bind and remove toxin A from a sample suspected of containing said toxin A, which method comprises contacting said sample with an oligosaccharide sequence covalently attached to a solid, inert support through a non-peptidyl compatible linker arm, wherein said oligosaccharide sequence binds toxin A, under conditions wherein said toxin A is absorbed to said support; and separating the support containing the absorbed toxin A from the sample.
In another aspect, the invention provides a method to treat diarrhea mediated by toxin A in a subject, which method comprises administering to a subject in need of such treatment an effective amount of a composition comprising an oligosaccharide sequence covalently attached to a pharmaceutically acceptable solid, inert support through a non-peptidyl compatible linker arm, wherein said oligosaccharide sequence binds toxin A, and wherein said composition is capable of being eliminated from the gastrointestinal tract.
In a further aspect, the invention provides a pharmaceutical composition useful in treating CDAD and related conditions initiated by toxin A, which composition comprises an oligosaccharide sequence covalently attached to a pharmaceutically acceptable solid, inert support through a non-peptidyl compatible linker arm, wherein said oligosaccharide sequence binds toxin A; and a pharmaceutically acceptable carrier, wherein said composition is capable of being eliminated from the gastrointestinal tract.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 demonstrates the neutralization of purified toxin A hemagglutination activity using a panel of SYNSORBs containing various oligosaccharide sequences. Several SYNSORBs were found to effectively neutralize toxin A activity.
FIG. 2 illustrates the concentration dependent neutralization of toxin A activity using SYNSORB 52 and 90. Both SYNSORBs can effectively neutralize more than about 75% of toxin A activity at a concentration of 20 mg/ml.
FIG. 3 demonstrates the time dependency of neutralization of toxin A activity using SYNSORB 52 and 90 at a concentration of 20 mg/ml.
FIG. 4 illustrates the binding affinity of several SYNSORBs for toxin A. Different SYNSORBs were found to have different binding affinities for the toxin.
DETAILED DESCRIPTION OF THE INVENTION A. Definitions
As used herein the following terms have the following meanings:
The term "antibiotic-associated bacterial diarrhea" refers to the condition wherein antibiotic therapy disturbs the balance of the microbiol flora of the gut, allowing pathogenic organisms such as Clostridium difficile to flourish. These organisms cause diarrhea. Antibiotic-associated bacterial diarrhea includes such conditions as Clostridium difficile associated diarrhea (CDAD) and pseudomembranous colitis (PMC).
The term "biocompatible" refers to chemical inertness with respect to human tissues or body fluids.
The term "compatible linker arm" refers to a moiety which serves to space the oligosaccharide structure from the biocompatible solid support and which is biofunctional wherein one functional group is capable of binding to a reciprocal functional group of the support and the other functional group is capable of binding to a reciprocal functional group of the oligosaccharide structure. Compatible linker arms preferred in the present invention are non-peptidyl spacer arms.
The term "pseudomembranous colitis" (PMC), also known as pseudomembranous enterocolitis or enteritis, refers to the inflammation of the mucous membrane of both small and large intestine with the formation and passage of pseudomembranous material (composed of fibrin, mucous, necrotic epithelial cells and leukocytes) in the stools.
The term "solid support" refers to an inert, solid material to which the oligosaccharide sequences may be bound via a compatible linker arm. Where use is in vivo, the solid support will be biocompatible.
The term "SYNSORB" refers to synthetic 8-methoxycarbonyloctyl oligosaccharide structures covalently coupled to Chromosorb P™ (Manville Corp., Denver, Colo.) (12), which is a derivitized silica particle.
The term "toxin A" refers to an enterotoxin of Clostridium difficile which initiates CDAD and related conditions. This toxin has a lectin-like activity.
For purpose of this application, all sugars are referenced using conventional three letter nomenclature. All sugars are assumed to be in the D-form unless otherwise noted, except for fucose, which is in the L-form. Further all sugars are in the pyranose form.
B. Synthesis
Chemical methods for the synthesis of oligosaccharide structures can be accomplished by methods known in the art. These materials are generally assembled using suitably protected individual monosaccharides.
The specific methods employed are generally adapted and optimized for each individual structure to be synthesized. In general, the chemical synthesis of all or part of the oligosaccharide glycosides first involves formation of a glycosidic linkage on the anomeric carbon atom of the reducing sugar or monosaccharide. Specifically, an appropriately protected form of a naturally occurring or of a chemically modified saccharide structure (the glycosyl donor) is selectively modified at the anomeric center of the reducing unit so as to introduce a leaving group comprising halides, trichloroacetimidate, acetyl, thioglycoside, etc. The donor is then reacted under catalytic conditions well known in the art with an aglycon or an appropriate form of a carbohydrate acceptor which possesses one free hydroxyl group at the position where the glycosidic linkage is to be established. A large variety of aglycon moieties are known in the art and can be attached with the proper configuration to the anomeric center of the reducing unit.
Appropriate use of compatible blocking groups, well known in the art of carbohydrate synthesis, will allow selective modification of the synthesized structures or the further attachment of additional sugar units or sugar blocks to the acceptor structures.
After formation of the glycosidic linkage, the saccharide glycoside can be used to effect coupling of additional saccharide unit(s) or chemically modified at selected positions or, after conventional deprotection, used in an enzymatic synthesis. In general, chemical coupling of a naturally occurring or chemically modified saccharide unit to the saccharide glycoside is accomplished by employing established chemistry well documented in the literature [21-37].
The solid supports to which the oligosaccharide structures of the present invention are bound may be in the form of sheets or particles. A large variety of biocompatible solid support materials are known in the art. Examples thereof are silica, synthetic silicates such as porous glass, biogenic silicates such as diatomaceous earth, silicate-containing minerals such as kaolinite, and synthetic polymers such as polystyrene, polypropylene, and polysaccharides. Preferably the solid supports have a particle size of from about 10 to 500 microns for in vivo use. In particular, particle sizes of 100 to 200 microns are preferred.
The oligosaccharide structure(s) is covalently bound or noncovalently (passively) adsorbed onto the solid support. The covalent bonding may be via reaction between functional groups on the support and the compatible linker arm of the oligosaccharide structure. It has unexpectedly been found that attachment of the oligosaccharide structure to the biocompatible solid support through a compatible linking arm provides a product which, notwithstanding the solid support, effectively removes toxin. Linking moieties that are used in indirect bonding are preferably organic biofunctional molecules of appropriate length (at least one carbon atom) which serve simply to distance the oligosaccharide structure from the surface of the solid support.
The compositions of this invention are preferably represented by the formula:
(OLIGOSACCHARIDE--Y--R).sub.n -- SOLID SUPPORT
where OLIGOSACCHARIDE represents an oligosaccharide group of at least 2 sugar units which group binds to toxin A, Y is oxygen, sulfur or nitrogen, R is an aglycon linking arm of at least 1 carbon atom, SOLID SUPPORT is as defined above, and n is an integer greater than or equal to 1. Oligosaccharide sequences containing about 2 to 10 saccharide units may be used. Sequences with about 3 to 5 saccharide units are preferred.
Numerous aglycon linking arms are known in the art. For example, a linking arm comprising a para-nitrophenyl group (i.e., --OC6 H4 pNO2) has been disclosed [38]. At the appropriate time during synthesis, the nitro group is reduced to an amino group which can be protected as N-trifluoroacetamido. Prior to coupling to a support, the trifluoroacetamido group is removed thereby unmasking the amino group.
A linking arm containing sulfur has been disclosed [39]. Specifically, the linking arm is derived from a 2-bromoethyl group which, in a substitution reaction with thionucleophiles, has been shown to lead to linking arms possessing a variety of terminal functional groups such as --OCH2 CH2 SCH2 CO2 CH3 and --OCH2 CH2 SC6 H4 --pNH2. These terminal functional groups permit reaction to complementary functional groups on the solid support, thereby forming a covalent linkage to the solid support. Such reactions are well known in the art.
A 6-trifluoroacetamido-hexyl linking arm (--O--(CH2)6 --NHCOCF3) has been disclosed [40] in which the trifluoroacetamido protecting group can be removed, unmasking the primary amino group used for coupling.
Other exemplifications of known linking arms include the 7-methoxycarbonyl-3,6,dioxaheptyl linking arm [41] (--OCH2 --CH2)2 OCH2 CO2 CH3); the 2-(4-methoxycarbonylbutancarboxamido)ethyl [42] (--OCH2 CH2 NHC(O)(CH2)4 CO2 CH3); the allyl linking arm [43] (--OCH2 CH═CH2) which, by radical co-polymerization with an appropriate monomer, leads to co-polymers; other allyl linking arms [44] are known [--O(CH2 CH2 O)2 CH2 CH═CH2 ]. Additionally, allyl linking arms can be derivatized in the presence of 2-aminoethanethiol [45] to provide for a linking arm --OCH2 CH2 CH2 SCH2 CH2 NH2. Other suitable linking arms have also been disclosed [21-23, 25, 26].
The particular linking employed to covalently attach the oligosaccharide group to the solid support is not critical.
Preferably, the aglycon linking arm is a hydrophobic group and most preferably, the aglycon linking arm is a hydrophobic group selected from the group consisting of ##STR1##
We have found that synthetic oligosaccharide sequences covalently attached to a biocompatible solid support, e.g., Chromosorb P™ (SYNSORB) may be used to bind toxin A. These compositions are useful to treat CDAD and PMC. SYNSORB is particularly preferred for these compositions because it is non-toxic and resistant to mechanical and chemical deposition. In studies using rats (a widely accepted model for preclinical studies, since they are predictive of human response), SYNSORBs have been found to pass unaffected through the rat gastrointestinal tract. They were found to be eliminated completely and rapidly (99% eliminated in 72 hours) following oral administration.
Additionally, the high density of oligosaccharide moieties on SYNSORB is particularly useful for binding toxin A, since the toxin is thought to possess multiple oligosaccharide binding sites [11].
Non-peptidyl linking arms are preferred for use as the compatible linking arms of the present invention. The use of glycopeptides is not desirable because glycopeptides contain several, often different, oligosaccharides linked to the same protein. Glycopeptides are also difficult to obtain in large amounts and require expensive and tedious purification. Likewise, the use of BSA or HSA conjugates is not desirable due to questionable stability in the gastrointestinal tract when given orally.
Covalent attachment of an oligosaccharide group containing a toxin A binding unit through a non-peptidyl spacer arm to an inert solid support permits efficient binding and removal of toxin A from a sample to be analyzed for the presence of toxin A or from the intestine of a patient suffering from CDAD. When the oligosaccharide is synthesized with this compatible linker arm attached (in non-derivatized form), highly pure compositions may be achieved which can be coupled to various solid supports.
C. Pharmaceutical Compositions
The methods of this invention are achieved by using pharmaceutical compositions comprising one or more oligosaccharide structures which bind toxin A attached to a solid support.
When used for oral administration, which is preferred, these compositions may be formulated in a variety of ways. It will preferably be in liquid or semisolid form. Compositions including a liquid pharmaceutically inert carrier such as water may be considered for oral administration. Other pharmaceutically compatible liquids or semisolids, may also be used. The use of such liquids and semisolids is well known to those of skill in the art.
Compositions which may be mixed with semisolid foods such as applesauce, ice cream or pudding may also be preferred. Formulations, such as SYNSORBs, which do not have a disagreeable taste or aftertaste are preferred. A nasogastric tube may also be used to deliver the compositions directly into the stomach.
Solid compositions may also be used, and may optionally and conveniently be used in formulations containing a pharmaceutically inert carrier, including conventional solid carriers such as lactose, starch, dextrin or magnesium stearate, which are conveniently presented in tablet or capsule form. The SYNSORB itself may also be used without the addition of inert pharmaceutical carriers, particularly for use in capsule form.
Doses are selected to provide neutralization and elimination of the toxin A found in the gut of the effected patient. Useful doses are from about 0.25 to 1.25 micromoles of oligosaccharide/kg body weight/day, preferably about 0.5 to 1.0 micromoles of oligosaccharide/kg body weight/day. Using SYNSORB compositions, this means about 0.5 to 1.0 gram SYNSORB/kg body weight/day, which gives a concentration of SYNSORB in the gut of about 20 mg/ml. Administration is expected to be 3 or 4 times daily, for a period of one week or until clinical symptoms are resolved. The dose level and schedule of administration may vary depending on the particular oligosaccharide structure used and such factors as the age and condition of the subject. Optimal time for complete removal of toxin A activity was found to be about 1 hour at 37° C., using a concentration of SYNSORB of 20 mg in 1 ml sample.
Administration of the oligosaccharide-containing compositions of the present invention during a period of up to seven days will be useful in treating CDAD and PMC.
As discussed previously, oral administration is preferred, but formulations may also be considered for other means of administration such as per rectum. The usefulness of these formulations may depend on the particular composition used and the particular subject receiving the treatment. These formulations may contain a liquid carrier that may be oily, aqueous, emulsified or contain certain solvents suitable to the mode of administration.
Compositions may be formulated in unit dose form, or in multiple or subunit doses. For the expected doses set forth previously, orally administered liquid compositions should preferably contain about 1 micromole oligosaccharide/ml.
D. Methodology
We have found that C. difficile toxin A may be neutralized by certain oligosaccharide sequences which bind the toxin. In particular, synthetic oligosaccharides covalently attached to solid supports via non-peptidyl compatible linker arms have been found to neutralize toxin A effectively. Examples of such compositions are certain SYNSORBs, which bind and neutralize toxin A activity.
We have tested the ability of several oligosaccharide sequences attached to Chromosorb P via an 8-methoxylcarbonyloctyl (MCO) spacer arm to neutralize toxin A. The structures tested, also referred to as SYNSORBs, are presented in Table 1. As shown in FIGS. 1 and 4, the SYNSORBs tested varied in their ability to neutralize at least about 50% of the toxin A activity.
The oligosaccharide sequences attached to solid supports useful in the present invention are those which bind toxin A. The binding affinity of an oligosaccharide to toxin A is readily detectable by a simple in vitro test, as for example, set forth in Example 4 below. For the purposes of this invention, oligosaccharide sequences attached to solid supports which bind toxin A means those compositions which reduce endpoint titers from hemagglutination assays by at least 50%.
Certain of the SYNSORBs tested as described above were then used to study the ability of these oligosaccharide compositions to neutralize toxin A in human stool samples.
The binding of shiga-like toxins (SLTs) to chemically synthesized oligosaccharide sequences has been studied [10].
SLTs are a group of cytoxins which are made up of two parts: an A subunit and a B oligomer. The B oligomer is the binding portion of the toxin that allows it to bind to host cell receptors. The SLT toxins bind to glycolipid receptors containing the αGal(1-4)βGal determinant. The A subunit has an enzymatic activity (N-glycosidase) that depurinates 28S ribosomal RNA in mammalian cells. This enzymatic activity abolishes the ability of the toxin-infected cell to perform protein synthesis.
The site for SLT action is endothelial cells found in the kidneys and mesenteric vasculature, and SLTs may cause damage that can result in renal failure and hemoglobin in the urine. SLTs are the causative agent in the hemolytic-uremic syndrome. SLTs may also be partially involved in the pathogenesis of hemorrhagic colitis (bloody diarrhea).
In contrast, toxin A is an enterotoxin that induces fluid secretion, mucosal damage and intestinal inflammation. It serves as a chemoattractant for human neutrophils. Toxin A is a single protein. It cause activation and results in the release of cytokines in monocytes. These inflammatory effects may play an important role in inducing the colonic inflammation seen in pseudomembranous colitis.
Toxin A appears to bind to a glycoprotein receptor, the structure of which has yet to be determined. The mechanism of action is not totally understood, but toxin A is thought to enter cells via receptor-mediated endocytosis and affect the actin cytoskeleton of the cell. The toxin A receptor is thought to be linked to a guanine regulatory protein. Toxin A is the first step in the production of CDAD and PMC.
Previous studies defining the oligosaccharide binding specificity of toxin A have identified several structural requirements for toxin binding [5-7]. Oligosaccharides which terminate in the α-Gal(1-3)βGal sequences attached to the type 2 core (βGal(1-4)βGlcNAc) have been shown to be important for binding. In addition, toxin A also recognizes oligosaccharides with fucose attached to the 2 hydroxyl of galactose or the 3 hydroxyl of N-acetylglucosamine of the type 2 core. The SYNSORBs chosen for toxin neutralization studies include carbohydrates which incorporate these structural features as well as other oligosaccharides which encompass the type 6 (βGal(1-4)βGlc) and type 1(βGal(1-3)βGlcNAc) core structures. Additional SYNSORBs selected for binding studies contain oligosaccharide sequences previously shown to bind to toxin A.
The amount of toxin A adsorption to SYNSORB was determined by assaying supernatants for reduction of endpoint titers in hemagglutination assays relative to controls without any added SYNSORB. Results are shown in FIG. 1. Those SYNSORBs which possessed the X, Y, and αGal(1-3)βGal(1-4)βGlcNAc oligosaccharide sequences (SYNSORBs 51, 52, and 115) were found to effectively remove toxin A activity by 75, 88, and 88%, respectively. In addition, two other SYNSORBs which contained oligosaccharide sequences not previously shown to bind toxin A (SYNSORBs 9 and 90) were as effective at neutralizing toxin A activity. SYNSORBs 2, 5, 104, 105, and 134 neutralized about 50% of toxin A activity. The control SYNSORB (ASA), which contains only the MCO spacer arm only slightly neutralized toxin A activity.
Thus, we have found that the ability to neutralize toxin A is directly related to the oligosaccharide sequences attached to the inert support. The results in FIG. 1 show the importance of the αGal(1-3)βGal linkage for high affinity toxin binding. In addition, we have found that oligosaccharide sequences which possess a β(1-4) linkage between galactose and either N-acetylglucosamine (type 2 core) or glucose (type 6) show high affinity toxin binding. We have further found that toxin A binds oligosaccharide sequences having fucose attached to the 2 hydroxyl of galactose only.
The results presented in FIGS. 1 and 4 show reduction in endpoint titers from hemagglutination assays. Similar results were obtained in tissue culture assays using Chinese Hamster Ovary (CHO) cells. These studies demonstrated that the CHO cells showed a reduction in endpoint dilution relative to controls when SYNSORB was added to purified toxin A preparations.
Several different oligosaccharide sequences attached to solid supports via compatible linker arms have been found to have the ability to neutralize toxin A activity. These sequences, and others that also bind toxin A, may be used to treat CDAD and PMC. Optimal time for complete removal of toxin A activity was found to be about 1 hour at 37° C., using a concentration of SYNSORB of 20 mg in 1 ml sample. Since each gram of SYNSORB contains approximately 0.25 to 1.0 micromoles oligosaccharide, the total amount of oligosaccharide to be given in a daily dose would range from 7.5 to 30 micromoles, using a gut volume of four liters.
The utility of oligosaccharide sequences attached to a solid support via a compatible linker arm to treat CDAD and PMC was also demonstrated by the ability of SYNSORB compositions to neutralize toxin A in human stool samples. These tests on human samples are predictive of in vivo results, since there are essentially no compositional or chemical changes between the in vitro conditions of this assay and in vivo conditions. Further, the assay conditions approximate the actual conditions found in the human intestine. This test has been accepted by those skilled in the art as appropriately correlated with human utility.
The results, shown in Table 2, show that SYNSORB 52 was effective in neutralizing toxin A activity in human stool samples. Generally, greater amounts of toxin in watery stools were more effectively neutralized. The toxin in solid stool samples containing only low levels of toxin was less effectively neutralized.
Treatment of CDAD or PMC may be accomplished by oral administration of compositions containing oligosaccharide sequences covalently bound to a solid support via a compatible linker arm (e.g. SYNSORBs). For example, the SYNSORB has been found to pass through the stomach of rats intact. It then contacts the toxin A in the intestinal tract. Subsequent elimination of the intact SYNSORB with toxin A bound to it results in elimination of toxin A from the patient.
Oligosaccharide sequences covalently attached via compatible linker arms to solid support, e.g. SYNSORBs, are useful to treat individuals who suffer from multiple episodes of diarrhea. Upon initial reoccurrence of diarrhea, patients would be treated with SYNSORB to remove toxin A from the intestine. The removal of toxin A prevents the initial tissue damage to the intestinal lining, which leads to prevention or reduction of diarrhea. No further treatment with antibiotics need be given, allowing the reestablishment of the normal intestinal microflora within the gut. The advantage of such treatment is that it does not affect the recolonization of the intestinal tract by normal microflora. Treatment until discontinuance of diarrhea would allow complete recovery.
In addition to its usefulness in patients suffering from recurring diarrhea, treatment with oligosaccharide sequences covalently attached via compatible linker arms to solid supports, e.g. SYNSORBs, may be used to treat all individuals who suffer from or are prone to develop CDAD or PMC. The use of SYNSORB in combination with antibiotic therapy will be able to reduce the diarrhea more effectively, leading to more rapid recovery.
A major aspect of the invention is the rapid efficient binding of physiological concentration of toxin A present in biological samples, thus permitting assay of the presence and/or quantity of toxin A in these samples. Typically, the biological sample will be a stool sample. The sample may be extracted and prepared using standard extraction techniques. The sample or extract is then contacted with the toxin-binding oligosaccharide sequences covalently bound to solid supports via a compatible linker arm under conditions where any toxin A in the sample is absorbed.
Toxin A may be measured directly on the surface of the oligosaccharide-containing support using any suitable detection system. For example, radioactive, biotinylated or fluorescently labelled monoclonal or polyclonal antibodies specific for toxin A may be used to determine the amount of toxin A bound to the support. A wide variety of protocols for detection of formation of specific binding complexes analogous to standard immunoassay techniques is well known in the art.
E. Examples
The following methods were used to perform the studies in the Examples that follow.
1. Toxin A Purification:
Toxin A was isolated from a toxin producing strain of C. difficile (ATCC 43255, VPI strain 10463) using slight modifications of the method of Sullivan et al. [13].
C. difficile was grown in 2.3 liter of brain heart infusion broth (BHIB) in anaerobic jars for 72 hours at 37° C. The crude culture was centrifuged at 5,000× g for 20 minutes to sediment the bacteria. The resulting culture supernatant was carefully removed and solid ammonium sulfate (897 g) was added to make 60% saturation. The culture supernatant was stirred at 4° C. overnight and then centrifuged at 10,000× g for 30 minutes. The resulting pellet was dissolved in a minimum amount of buffer A (50 mM sodium phosphate buffer, pH 7.5), dialyzed against 2-4 liter changes of buffer A and concentrated by ultrafiltration using a YM 100 (100,000 molecular weight cutoff) membrane.
The concentrated toxin-containing solution was loaded onto a DEAE-Sephadex A-25 column (2.5×20 cm) equilibrated with buffer A. After washing the ion exchange resin with buffer A to remove non-adherent protein, the column was developed with a stepwise salt gradient by washing with buffer A containing increasing amounts of NaCl ranging from 0.1 to 0.4M. Toxin A activity was eluted from the column with buffer A containing 0.25M NaCl, while toxin B activity was removed with 0.4M NaCl buffer A.
The overall purity and amount of toxin from each fraction was determined by measuring the protein concentration, as well as using a cytotoxic endpoint using Chinese hamster ovary (CHO) cells. The amount of toxin A activity was also determined by measuring the hemagglutination activity using rabbit erythrocytes. The toxin B fraction was devoid of toxin A activity, as determined by the inability of the toxin B-containing fraction to hemagglutinate rabbit erythrocytes.
2. Hemagglutination Assays Using Rabbit Erythrocytes
Fresh rabbit erythrocytes were washed once in phosphate buffered saline (PBS) and resuspended at a concentration of 4% (v/v) in cold PBS. Serial 2-fold dilutions (50 μl) of toxin A-containing solutions were made in cold PBS in U-shaped microtiter wells. An equal volume (50 μl) of rabbit erythrocytes was then added to each well and the microtiter plate was mixed gently. After incubating the plate for 4 hours at 4° C., the hemagglutination titer was visually assessed.
3. Assay of Toxin Activity Using Chinese Hamster Ovary Cells
The cytotoxic activity of toxin A was measured by the use of Chinese Hamster Ovary (CHO) cells that were maintained in Hams F12 media supplemented with 10% fetal bovine serum in an atmosphere of 5% CO2 at 37° C.
Toxin A samples to be tested were diluted 1:10 in Hams media and filter sterilized through 0.22 micron syringe filters. Samples to be tested were serial 5-fold diluted in media and 100 μl of each dilution was added to wells with confluent monolayers of CHO cells, then incubated for 24 hours at 37° C. in an atmosphere of 5% CO2. Each sample was analyzed in duplicate.
Cytotoxic effects were readily visible after 24 hour incubation by comparing wells with controls that did not contain toxin A. After 24 hours, the cells were fixed with 95% methanol and stained with Giemsa stain. Percent neutralization in the neutralization studies was determined by comparing the endpoint dilutions of samples with and without SYNSORB.
The following examples are offered to illustrate this invention and are not meant to be construed in any way as limiting the scope of this invention.
EXAMPLE 1 Screening of Oligosaccharide-containing Solid Supports for the Ability to Neutralize Toxin A Activity
A solution containing purified toxin A prepared as described above (0.5 ml) was added to various SYNSORBs containing different oligosaccharide sequences covalently attached to a solid support via an MCO compatible linker arm. The amount of SYNSORB used ranged from 10.1 to 17.5 mg. The samples were prepared in 1.5 ml microcentrifuge tubes which were incubated at room temperature for 2 hours on an end-over-end rotator.
After incubation, the SYNSORB was allowed to settle to the bottom of the tubes and the supernatants were carefully removed. Serial 2-fold dilutions of the supernatants were prepared and the hemagglutination endpoint determined as described above.
The extent of reduction in the endpoint in the presence of SYNSORB was determined by comparing the endpoint with that of controls in which SYNSORB was not added. An additional control utilized SYNSORB (ASA) that contained only the MCO (hydrophobic 8 carbon) spacer arm.
Results are shown in FIG. 1, and demonstrate that several oligosaccharide structures were found to effectively neutralize toxin A activity.
EXAMPLE 2 Determination of Optimal Binding Conditions Using SYNSORBs 52 and 90
The amount of SYNSORBS 52 and 90 required for maximal toxin A neutralization was determined by adding 1 ml of a purified toxin A solution to pre-weighed amounts of each SYNSORB in 1.5 ml microcentrifuge tubes. SYNSORB 52 samples were tested using 12.8, 21.6 and 43.3 mg amounts of SYNSORB 52; SYNSORB 90 samples were tested using 12.9, 19.2 and 42.3 mg amounts of SYNSORB 90. Samples were incubated for 2 hours at 37° C. on an end-over-end rotator. Control samples containing only toxin A solution were also tested.
The amount of neutralization in each sample was determined by comparing the endpoint titers of hemagglutination assays from samples with and without SYNSORB. The results, shown in FIG. 2, demonstrate that about 20 mg of each SYNSORB tested was able to neutralize at least 75% of the toxin A in 1 ml of toxin A solution.
The length of incubation time required for optimal neutralization was determined by incubating microcentrifuge tubes containing 1 ml of purified toxin A solution and 20 mg of either SYNSORB 52 or SYNSORB 90. Samples were incubated at 37° C. on an end-over-end rotator for 10, 20, 40, 80 or 160 minutes.
The degree of neutralization at each incubation period was determined as described above. The results, shown in FIG. 3, demonstrate that about 1 hour incubation (between 40 and 80 minutes) resulted in effective neutralization of toxin A.
EXAMPLE 3 Neutralization of Toxin A Activity in Toxin-Positive Human Stool Samples
Toxin A positive human stool samples were obtained from University of Alberta Hospital's Microbiology Laboratory. One ml of each stool sample was placed in a 1.5 ml microcentrifuge tube, 20 mg SYNSORB 52 (pre-wetted with 50 μl PBS) was added, and the tubes were incubated on an end-over-end rotator for 4 hours at 37° C. Control stool samples without SYNSORB were also tested simultaneously. After incubation the stool samples were centrifuged at 14,000 rpm in an Eppendorf Microcentrifuge for 10 minutes. The resulting supernatants were carefully removed and placed into clean microcentrifuge tubes.
The amount of toxin A in each sample was determined by using the PREMIER™ C. difficile Toxin A detection kit (Meridian Diagnostics, Cincinnati, Ohio). The percent neutralization was assessed by measuring the reduction in the absorbance at 450 nm relative to individual control samples without added SYNSORB.
Results, shown in Table 2, demonstrate that SYNSORB 52 was able to neutralize toxin A activity in human biological samples.
EXAMPLE 4 Determination of Binding Affinity
To assess the binding affinity of various SYNSORBs to toxin A, each SYNSORB was combined with toxin A as described in Example 1. Endpoint titers from hemagglutination assays using rabbit erythocytes were determined as described previously. SYNSORBs that were more effective at neutralizing toxin A activity possessed oligosaccharide structures that bound to toxin A with higher affinities. Those SYNSORBs which reduced titers by greater than 50% were deemed to bind toxin A.
Results are shown in FIG. 4, and demonstrated that some SYNSORBs (SYNSORBs 52 and 68) bind toxin A by this criteria, while others (SYNSORBs 34 and 89) appear not to bind toxin A.
Modification of the above-described modes of carrying out various embodiments of this invention will be apparent to those skilled in the art following the teachings of this invention as set forth herein. The examples described above are not limiting, but are merely exemplary of this invention, the scope of which is defined by the following claims.
              TABLE 1                                                     
______________________________________                                    
SYNSORBs utilized in toxin A neutralization studies                       
SYN-   Struc-                                                             
SORB   ture     Common    Oligosaccharide                                 
Number Number   Name      Structure*                                      
______________________________________                                    
 2     1        B         αGal(1-3)βGal                        
                          (1-2)                                           
                          αFuc                                      
 5     2        H Type 2  βGal(1-4)βGlcNAc                      
                          (1-2)                                           
                          αFuc                                      
 9     3        B Type 2  αGal(1-3)βGal(1-4)βGlcNAc       
                          (1-2)                                           
                          αFuc                                      
34     4        N-Acetyl- βGal(1-4)βGlcNAc                      
                lactosamine                                               
51     5        X         βGal(1-4)βGlcNAc                      
                          (1-3)                                           
                          αFuc                                      
52     6        Y         βGal(1-4)βGlcNAc                      
                          (1-2)  (1-3)                                    
                          αFuc  αFuc                          
68     7        Pk        αGal(1-4)βGal(1-4)βGlc          
89     8        sialyl-   αNeuAc(2-6)βGal(1-4)βGlc        
                lactose                                                   
90     9        --        αGal(1-3)βGal(1-4)βGlc          
104    10       H Type 6  βGal(1-4)βGlc                         
                          (1-2)                                           
                          αFuc                                      
105    11       B Type 6  αGal(1-3)βGal(1-4)βGlc          
                          (1-2)                                           
                          αFuc                                      
115    12       --        αGal(1-3)βGal(1-4)βGlcNAc       
134    13       --        αGal(1-3)βGal(1-3)βGlcNAc       
______________________________________                                    
 *All oligosaccharides are linked to Chromosorb P through the standard    
 hydrophobic 8 carbon spacer arm.                                         

              TABLE 2                                                     
______________________________________                                    
Neutralization of toxin A activity in stool                               
samples with SNYSORB 52                                                   
Toxin A Levels           Percent                                          
in Stool Samples.sup.a                                                    
             Type of Stool.sup.b                                          
                         Neutralization                                   
______________________________________                                    
++++         SS          96                                               
++++         SW          80                                               
++++         SW          77                                               
++++         W           70                                               
++++         SS          64                                               
+++          SW          63                                               
++           W           80                                               
++           W           72                                               
++           SW          46                                               
+            S           50                                               
+            S           42                                               
+            W           35                                               
+            W            0                                               
______________________________________                                    
.sup.a Toxin A levels in stool samples were determined by the use of      
PREMIER ™ C. difficile Toxin A detection kit.                          
The positive signs in Table 2 represent the relative amount of            
toxin A in each sample as determined by the absorbance at                 
450 nm as shown below. The mean percent neutralization using              
SYNSORB52 with respect to toxin A levels in stool samples are             
also shown.                                                               
.sup.A 450 Mean Percent Neutralization                                    
++++   > 1.5   77 ± 12%                                                
                         (n = 5)                                          
+++    1.1-1.4 63%       (n = 1)                                          
++     0.6-1.0 66 ± 18%                                                
                         (n = 3)                                          
+      0.1-0.4 32 ± 22%                                                
                         (n = 3)                                          
.sup.b The overall consistency of the stool samples examined.             
The abbreviations S, SS, SW and W refer to solid, semi-solid,             
semi-watery and watery respectively. The mean percent                     
neutralization of toxin A activity using SYNSORB 52 with                  
respect to stool consistency are as follows: S(31 ± 27%,               
n = 3), SS (80 ± 23%, n = 2),                                          
SW (67 ± 16%, n = 4) and W(62 ± 19%, n = 4).

Claims (14)

What is claimed is:
1. A method to treat diarrhea mediated by toxin A in a subject, which method comprises administering to a subject in need of such treatment an effective amount of a composition comprising an oligosaccharide sequence covalently attached to a pharmaceutically acceptable solid, inert support through a non-peptidyl compatible linker arm, wherein said oligosaccharide sequence binds toxin A, and wherein said composition is capable of being eliminated from the gastrointestinal tract.
2. The method of claim 1 wherein said oligosaccharide sequence has from 2 to 10 saccharide units.
3. The method of claim 1 wherein said oligosaccharide sequence is selected from the group consisting of the oligosaccharide structures numbers 1-3, 5-7, and 9-13 set forth in Table 1.
4. The method of claim 1 wherein said oligosaccharide sequence covalently attached to a pharmaceutically acceptable solid, inert support through a non-peptidyl compatible linker arm is selected from the group consisting of SYNSORBs 2, 5, 9, 51, 52, 68, 90, 104, 105, 115, and 134 set forth in Table 1.
5. The method of claim 1 wherein said linker arm is --(CH2)8 C(O)--.
6. A method to treat diarrhea mediated by toxin A in a subject, which method comprises administering to a subject in need of such treatment an effective amount of a composition comprising an oligosaccharide sequence, wherein said oligosaccharide sequence is selected from the group consisting of the oligosaccharide structures numbers 1-3, 7, and 9-13 set forth in Table 1, covalently attached to a pharmaceutically acceptable, solid, inert support through a non-peptidyl compatible linker arm, wherein said oligosaccharide sequence binds toxin A and wherein said composition is capable of being eliminated from the gastrointestinal tract.
7. The method of claim 6 wherein said solid, inert support through a non-peptidyl compatible linker arm is --(CH2)8 C(O)-- selected from the group consisting of SYNSORBs 2, 5, 9, 68, 90, 104, 105, 115 and 134 set forth in Table 1.
8. A pharmaceutical composition useful for in vivo treatment of CDAD and related conditions initiated in intervals by toxin A, which composition comprises:
a) an oligosaccharide sequence covalently attached to a pharmaceutically acceptable solid, inert support through a non-peptidyl compatible linker arm, wherein said oligosaccharide sequence binds toxin A; and
b) a pharmaceutically acceptable carrier, wherein said composition is capable of being eliminated from the gastrointestinal tract.
9. The composition of claim 8 wherein said oligosaccharide sequence has from 2 to 10 saccharide units.
10. The composition of claim 8 wherein said oligosaccharide sequence is selected from the group consisting of the oligosaccharide structures numbers 1-3, 5-7, and 9-13 set forth in Table 1.
11. The composition of claim 8 wherein said oligosaccharide sequence covalently attached to said pharmaceutically acceptable solid, inert support through a non-peptidyl compatible linker arm is selected from the group consisting of SYNSORBs 2, 5, 9, 51, 52, 68, 90, 104, 105, 115, and 134 set forth in Table 1.
12. The composition of claim 8 wherein said linker arm is --(CH2)8 C(O)--.
13. A pharmaceutical composition useful for in vivo treatment of CDAD and related conditions initiated in mammals by toxin A, which composition comprises:
a) an oligosaccharide sequence, wherein said oligosaccharide sequence is selected from the group consisting of the oligosaccharide structures numbers 1-3, 7, and 9-13 set forth in Table 1, covalently attached to a pharmaceutically acceptable solid, inert support through a non-peptidyl compatible linker arm, wherein said oligosaccharide sequence binds toxin A; and
b) a pharmaceutically acceptable carrier, wherein said composition is capable of being eliminated from the gastrointestinal tract.
14. The composition of claim 13 wherein said solid, inert support is Chromosorb P and said non-peptidyl compatible linker arm is --(CH2)8 C(O)-- selected from the group consisting of SYNSORBs 2, 5, 9, 68, 90, 104, 105, 115 and 134 set forth in Table 1.
US08/195,009 1994-02-14 1994-02-14 Treatment of antibiotic associated diarrhea Expired - Lifetime US5484773A (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
US08/195,009 US5484773A (en) 1994-02-14 1994-02-14 Treatment of antibiotic associated diarrhea
IL11242895A IL112428A (en) 1994-02-14 1995-01-24 Pharmaceutical compositions comprising an oligosaccharide sequence which bind toxin a of clostridium difficile
ZA95630A ZA95630B (en) 1994-02-14 1995-01-26 Treatment of antibiotic associated diarrhea
PCT/CA1995/000060 WO1995021628A1 (en) 1994-02-14 1995-02-09 Treatment of antibiotic associated diarrhea
NZ279180A NZ279180A (en) 1994-02-14 1995-02-09 Treating clostridium difficile associated diarrhea (cdad) and other antibiotic associated diarrhea using oligosaccharide compositions which bind toxin a
CA002181359A CA2181359C (en) 1994-02-14 1995-02-09 Treatment of antibiotic associated diarrhea
DE69533084T DE69533084T2 (en) 1994-02-14 1995-02-09 TREATMENT OF ANTIBIOTIC ASSOCIATED DIARRHOME
JP52086995A JP4122052B2 (en) 1994-02-14 1995-02-09 Treatment of antibiotic-related diarrhea
NZ328329A NZ328329A (en) 1994-02-14 1995-02-09 Treatment of antibiotic associated diarrhea using oligosaccharides
AT95907526T ATE267614T1 (en) 1994-02-14 1995-02-09 TREATMENT OF ANTIBIOTIC-ASSOCIATED DIARRHEA
CN95191615A CN1131070C (en) 1994-02-14 1995-02-09 Treatment of antibiotic associated diarrhea
EP95907526A EP0744959B1 (en) 1994-02-14 1995-02-09 Treatment of antibiotic associated diarrhea
AU15727/95A AU698275B2 (en) 1994-02-14 1995-02-09 Treatment of antibiotic associated diarrhea
US08/450,572 US5635606A (en) 1994-02-14 1995-05-25 Method of binding and removing toxin A
MX9603403A MX197129B (en) 1994-02-14 1996-08-13 Treatment of antibiotic associated diarrhea.
KR19967004399A KR970701064A (en) 1994-02-14 1996-08-13 Treatment of antibiotic associated diarrhea
NO963378A NO963378D0 (en) 1994-02-14 1996-08-13 Treatment of antibiotic-associated diarrhea

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/195,009 US5484773A (en) 1994-02-14 1994-02-14 Treatment of antibiotic associated diarrhea

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US08/450,572 Continuation US5635606A (en) 1994-02-14 1995-05-25 Method of binding and removing toxin A

Publications (1)

Publication Number Publication Date
US5484773A true US5484773A (en) 1996-01-16

Family

ID=22719705

Family Applications (2)

Application Number Title Priority Date Filing Date
US08/195,009 Expired - Lifetime US5484773A (en) 1994-02-14 1994-02-14 Treatment of antibiotic associated diarrhea
US08/450,572 Expired - Fee Related US5635606A (en) 1994-02-14 1995-05-25 Method of binding and removing toxin A

Family Applications After (1)

Application Number Title Priority Date Filing Date
US08/450,572 Expired - Fee Related US5635606A (en) 1994-02-14 1995-05-25 Method of binding and removing toxin A

Country Status (15)

Country Link
US (2) US5484773A (en)
EP (1) EP0744959B1 (en)
JP (1) JP4122052B2 (en)
KR (1) KR970701064A (en)
CN (1) CN1131070C (en)
AT (1) ATE267614T1 (en)
AU (1) AU698275B2 (en)
CA (1) CA2181359C (en)
DE (1) DE69533084T2 (en)
IL (1) IL112428A (en)
MX (1) MX197129B (en)
NO (1) NO963378D0 (en)
NZ (1) NZ279180A (en)
WO (1) WO1995021628A1 (en)
ZA (1) ZA95630B (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811409A (en) * 1995-06-05 1998-09-22 Synsorb Biotech, Inc. Treatment of cholera
US5846943A (en) * 1996-11-08 1998-12-08 Synsorb Biotech, Inc. Solid support matricles containing a toxin binding oligosaccharide
US5849714A (en) * 1996-06-21 1998-12-15 Synsorb Biotech Inc. Treatment of bacterial dysentery
WO1999001140A1 (en) * 1997-07-02 1999-01-14 Neose Technologies, Inc. Oligosaccharides for attenuating xenograft rejection and methods based thereon
US5955449A (en) * 1991-10-18 1999-09-21 Synsorb Biotech Inc. Diagnosis and treatment of bacterial dysentery
WO1999061031A1 (en) * 1998-05-28 1999-12-02 Synsorb Biotech, Inc. Treatment of c. difficile toxin b associated conditions
US6001819A (en) * 1995-06-07 1999-12-14 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
US6013634A (en) * 1996-11-08 2000-01-11 Synsorb Biotech, Inc. Solid support matrices containing a toxin binding oligosaccharide
US6270755B1 (en) 1999-05-13 2001-08-07 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders
US6290946B1 (en) 1999-05-13 2001-09-18 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders and antibacterial agents
US6358930B1 (en) 1998-05-28 2002-03-19 Synsorb Biotech Inc. Treatment of C. difficile toxin B associated conditions
US6596707B2 (en) * 2001-05-24 2003-07-22 Abbott Laboratories Monovalent saccharides and uses thereof
US6730295B2 (en) 2000-05-02 2004-05-04 Genzyme Corporation Anionic polymers as species specific antibacterial agents
US20060078534A1 (en) * 2004-10-13 2006-04-13 Dominique Charmot Toxin binding compositions
US20060099169A1 (en) * 2004-10-13 2006-05-11 Ilypsa, Inc. Toxin binding compositions
WO2006122835A1 (en) * 2005-05-18 2006-11-23 Da Volterra Colonic delivery of adsorbents
US20070053865A1 (en) * 2002-07-22 2007-03-08 Toni Chancellor-Adams Poly(potassium and sodium styrene sulfonate) its manufacture and its uses
US20070184120A1 (en) * 2003-10-01 2007-08-09 Clemson University Adhesin-specific nanoparticles and process for using same
WO2007132022A2 (en) * 2006-05-17 2007-11-22 Da Volterra Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
US20080089942A1 (en) * 2006-08-17 2008-04-17 Xavier Frapaise Use of adsorbent carbon microspheres to treat intestinal bacterial infections
US20120202753A1 (en) * 2009-07-06 2012-08-09 Children's Hospital Medical Center D/B/A Cincinnati Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
US8541168B1 (en) * 1995-03-10 2013-09-24 Jacob Wohlstadter Multi-array, multi-specific electrochemiluminescence testing
US9132142B2 (en) 2007-09-07 2015-09-15 The General Hospital Corporation Use of secretor, Lewis and sialyl antigen levels in clinical samples as predictors of risk for disease
US10626460B2 (en) 2013-02-21 2020-04-21 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
US10857167B2 (en) 2015-04-28 2020-12-08 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4428056A1 (en) * 1994-07-29 1996-02-08 Schering Ag Use of microparticle preparations to eliminate dissolved, non-renal substances from the blood
US5637576A (en) * 1995-06-05 1997-06-10 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
US5627163A (en) * 1995-06-05 1997-05-06 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
US5661131A (en) * 1995-06-05 1997-08-26 Synsorb Biotech, Inc. Treatment of cholera
US5891860A (en) * 1996-03-11 1999-04-06 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
US6069137A (en) * 1996-03-11 2000-05-30 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
US6063769A (en) * 1996-11-14 2000-05-16 Synsorb Biotech, Inc. 1-thiogalactose derivatives
US6087339A (en) * 1996-11-14 2000-07-11 Synsorb Biotech, Inc. Saccharide derivatives
US5968907A (en) * 1996-11-14 1999-10-19 Synsorb Biotech, Inc. 1-thiogalactose derivatives
US5932554A (en) * 1996-11-14 1999-08-03 Synsorb Biotech, Inc. 1-galactose derivatives
AU736031B2 (en) * 1996-11-15 2001-07-26 Synsorb Biotech Inc. Combinatorial synthesis of carbohydrate libraries
US5965719A (en) * 1996-11-15 1999-10-12 Sunsorb Biotech, Inc. Combinatorial synthesis of carbohydrate libraries
US20020019991A1 (en) * 1998-04-30 2002-02-14 Abbott Laboratories Compositions containing an alpha 1,2-fucose linkage and uses thereof
US6174867B1 (en) 1998-05-08 2001-01-16 Synsorb Biotech, Inc. 1-galactose derivatives having a carbon- or nitrogen-containing aglycon linkage
US6291435B1 (en) 1999-03-04 2001-09-18 The Governs Of The University Of Alberta Treatment of diarrhea caused by enteropathogenic Escherichia coli
MXPA06006392A (en) * 2003-12-05 2007-03-15 Childrens Hosp Medical Center Oligosaccharide compositions and use thereof in the treatment of infection.
US7915235B2 (en) * 2006-03-20 2011-03-29 Brian Dieckgraefe High affinity ligands bind to clostridium difficile toxin A
WO2007114683A1 (en) * 2006-03-30 2007-10-11 N.V. Nutricia Milk oligosaccharides for stimulating the immune system
CN108977497A (en) * 2018-06-12 2018-12-11 深圳市领治医学科技有限公司 A method of acquisition and depositary's trace fecal sample

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4137401A (en) * 1975-07-08 1979-01-30 Chembiomed Limited Glycoside-ether-ester compounds
US4362720A (en) * 1977-04-14 1982-12-07 Chembiomed Ltd. Synthesis of 2-amino-2-deoxyglycoses and 2-amino-2-deoxyglycosides from glycals
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
EP0319253A2 (en) * 1987-12-02 1989-06-07 Alberta Research Council Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
US4863852A (en) * 1985-07-03 1989-09-05 Virginia Tech Intellectual Properties, Inc. Method of detecting, isolating and purifying clostridium difficile toxin A and its receptors
US5098826A (en) * 1990-03-09 1992-03-24 Virginia Tech Intellectual Properties, Inc. Detection, isolation and purification of Clostridium difficile toxin A with toxin receptors
WO1993008209A1 (en) * 1991-10-18 1993-04-29 Chembiomed Ltd. Diagnosis and treatment of bacterial dysentery
US5266315A (en) * 1990-05-07 1993-11-30 Kabushiki Kaisha Miyarisan Seibutsu Igaku Kenkyusho Composite for Clostridium difficile diarrhea and pseudomembranous colitis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2857790C2 (en) * 1977-04-14 1983-12-22 Chembiomed Ltd., Edmonton, Alberta Process for the preparation of O-protected 2-azido-2-deoxy-glycosyl halides, some such compounds as such and their use

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4137401A (en) * 1975-07-08 1979-01-30 Chembiomed Limited Glycoside-ether-ester compounds
US4238473A (en) * 1975-07-08 1980-12-09 Chembiomed Limited Artificial oligosaccharide antigenic determinants
US4362720A (en) * 1977-04-14 1982-12-07 Chembiomed Ltd. Synthesis of 2-amino-2-deoxyglycoses and 2-amino-2-deoxyglycosides from glycals
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US4863852A (en) * 1985-07-03 1989-09-05 Virginia Tech Intellectual Properties, Inc. Method of detecting, isolating and purifying clostridium difficile toxin A and its receptors
EP0319253A2 (en) * 1987-12-02 1989-06-07 Alberta Research Council Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
US5079353A (en) * 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
US5098826A (en) * 1990-03-09 1992-03-24 Virginia Tech Intellectual Properties, Inc. Detection, isolation and purification of Clostridium difficile toxin A with toxin receptors
US5266315A (en) * 1990-05-07 1993-11-30 Kabushiki Kaisha Miyarisan Seibutsu Igaku Kenkyusho Composite for Clostridium difficile diarrhea and pseudomembranous colitis
WO1993008209A1 (en) * 1991-10-18 1993-04-29 Chembiomed Ltd. Diagnosis and treatment of bacterial dysentery

Non-Patent Citations (92)

* Cited by examiner, † Cited by third party
Title
Abbas, S. A., et al., "Tumor-Associated Oligosaccharides I: Synthesis of Sialyl-Lewisa Antigenic Determinant", Sialic Acids, Proc. Japan-German Symp. Berlin 22-23 (1988).
Abbas, S. A., et al., Tumor Associated Oligosaccharides I: Synthesis of Sialyl Lewis a Antigenic Determinant , Sialic Acids, Proc. Japan German Symp. Berlin 22 23 (1988). *
Amvam Zollo, P., et al., Streptococcus pneumoniae Type XIV Polysaccharide: Synthesis of a Repeating Branched Tetrasaccharide with Dioxa Type Spacer Arms , Carbohydrate Research, 150:199 212 (1986). *
Amvam-Zollo, P., et al., "Streptococcus pneumoniae Type XIV Polysaccharide: Synthesis of a Repeating Branched Tetrasaccharide with Dioxa-Type Spacer-Arms", Carbohydrate Research, 150:199-212 (1986).
Armstrong, G. D., et al., "Investigation of shiga-like toxin binding to chemically synthesized oligosaccharide sequences", J. Infect. Dis., 164:1160-7 (1991).
Armstrong, G. D., et al., Investigation of shiga like toxin binding to chemically synthesized oligosaccharide sequences , J. Infect. Dis., 164:1160 7 (1991). *
Barbut, F, et al., "Comparison of enterotoxin production, cytotoxin production, serogrouping and antimicrobial susceptibilities of Clostridium difficile strains isolated from AIDS and human immunodeficiency virus-negative patients", J. Clin. Microbiol. 31:740-2 (1993).
Barbut, F, et al., Comparison of enterotoxin production, cytotoxin production, serogrouping and antimicrobial susceptibilities of Clostridium difficile strains isolated from AIDS and human immunodeficiency virus negative patients , J. Clin. Microbiol. 31:740 2 (1993). *
Bartlett, J D, "Treatment of antibiotic-associated pseudomembranous colitis", Rev. Infect. Dis., 6, Suppl. 1:5235-41 (1984).
Bartlett, J D, Treatment of antibiotic associated pseudomembranous colitis , Rev. Infect. Dis., 6, Suppl. 1:5235 41 (1984). *
Bartlett, J G, et al., "Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia", N. Engl. J. Med. 298:531-534 (1978).
Bartlett, J G, et al., "Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis", Gastroenterology, 78:431-4 (1980).
Bartlett, J G, et al., Antibiotic associated pseudomembranous colitis due to toxin producing clostridia , N. Engl. J. Med. 298:531 534 (1978). *
Bartlett, J G, et al., Symptomatic relapse after oral vancomycin therapy of antibiotic associated pseudomembranous colitis , Gastroenterology, 78:431 4 (1980). *
Chernyak, A. Y., et al., "A New Type of Carbohydrate-Containing Synthetic Antigen: Synthesis of Carbohydrate-Containing Polyacrylamide Copolymers having the Specificity of 0:3 and 0:4 Factors of Salmonella", Carbohydrate Research, 128: 269-282 (1984).
Chernyak, A. Y., et al., A New Type of Carbohydrate Containing Synthetic Antigen: Synthesis of Carbohydrate Containing Polyacrylamide Copolymers having the Specificity of 0:3 and 0:4 Factors of Salmonella , Carbohydrate Research, 128: 269 282 (1984). *
Clark, G F, et al., "Toxin A from Clostridium difficile binds to rabbit erythrocyte glycolipids with terminal αGal(1-3)βGal(14)βGIcNAc sequences", Arch. Biochem. Biophys., 257:217-29 (1987).
Clark, G F, et al., Toxin A from Clostridium difficile binds to rabbit erythrocyte glycolipids with terminal Gal(1 3) Gal(14) GIcNAc sequences , Arch. Biochem. Biophys., 257:217 29 (1987). *
Cox, D., et al. "A New Synthesis of 4-O-α-D-Galactopyranosyl-D-Galacto-Pyranose", Carbohy. Res., 62: 245-252 (1978).
Cox, D., et al. A New Synthesis of 4 O D Galactopyranosyl D Galacto Pyranose , Carbohy. Res., 62: 245 252 (1978). *
Cozart, J C, et al., "Clostridium difficile diarrhea in patients with AIDS versus non-AIDS controls. Method of treatment and clinical response to treatment", J. Clin. Gastroenterol. 16:192-4 (1993).
Cozart, J C, et al., Clostridium difficile diarrhea in patients with AIDS versus non AIDS controls. Method of treatment and clinical response to treatment , J. Clin. Gastroenterol. 16:192 4 (1993). *
Dahm n, J., et al., 2 Bromoethyl glycosides: applications in the synthesis of spacer arm glycosides, Carbohydrate Research, 118: 292 301 (1983). *
Dahm n, J., et al., Synthesis of space arm, lipid, and ethyl glycosides of the trisaccharide portion D Gal (1 4) D GIc of the blood group p k antigen: preparation of neoglycoproteins , Carbohydrate Research, 127: 15 25 (1984). *
Dahmen, J., et al., "2-Bromoethyl glycosides: applications in the synthesis of spacer-arm glycosides," Carbohydrate Research, 118: 292-301 (1983).
Dahmen, J., et al., "Synthesis of space arm, lipid, and ethyl glycosides of the trisaccharide portion [α-D-Gal-(1-4)-β-D-GIc] of the blood group pk antigen: preparation of neoglycoproteins", Carbohydrate Research, 127: 15-25 (1984).
Ekborg, G., et al., "Synthesis of Three Disaccharides for the Preparation of Immunogens bearing Immunodeterminants Known to Occur on Glycoproteins", Carbohydrate Research, 110: 55-67 (1982).
Ekborg, G., et al., Synthesis of Three Disaccharides for the Preparation of Immunogens bearing Immunodeterminants Known to Occur on Glycoproteins , Carbohydrate Research, 110: 55 67 (1982). *
Eveillard, M. et al., "Identification and characterization of adhesive factors of Clostridium difficile involved in adhesion to human colonic enterocyte-like Caco-2 and mucus-secreting HT29 cells in culture", Molecular Microbiology, 7: 371-381 (1993).
Eveillard, M. et al., Identification and characterization of adhesive factors of Clostridium difficile involved in adhesion to human colonic enterocyte like Caco 2 and mucus secreting HT29 cells in culture , Molecular Microbiology, 7: 371 381 (1993). *
F gedi, P., et al., Thioglycosides as Glycosylating Agents in Oligosaccharide Synthesis , Glycoconjugate J., 4:97 108 (1987). *
Fernandez Santana, V., et al., Glycosides of Monoallyl Diethylene Glycol. A New type of Spacer group for Synthetic Oligosaccharides , J. Carbohydrate Chemistry, 8(3), 531 537 (1989). *
Fernandez-Santana, V., et al., "Glycosides of Monoallyl Diethylene Glycol. A New type of Spacer group for Synthetic Oligosaccharides", J. Carbohydrate Chemistry, 8(3), 531-537 (1989).
Finegold, S. M., et al., "Therapy directed against Clostridium difficile and its toxins. Complications of therapy". In Rolfe, R. D. et al. (eds) C. difficile: It's Role in Intestinal Disease, Academic Press, Inc., San Diego Calif. 341-57 (1988).
Finegold, S. M., et al., Therapy directed against Clostridium difficile and its toxins. Complications of therapy . In Rolfe, R. D. et al. (eds) C. difficile: It s Role in Intestinal Disease, Academic Press, Inc., San Diego Calif. 341 57 (1988). *
Fugedi, P., et al., "Thioglycosides as Glycosylating Agents in Oligosaccharide Synthesis", Glycoconjugate J., 4:97-108 (1987).
Garegg, P. J., et al., "A Synthesis of 8-Methoxycarbonyloct-1-yl O-α-D-Galactopyranosyl-(1→3)-O-β-D-Galactopyranosyl-(1.fwdarw.4)-2-Acetamido-2-Deoxy-β-D-Glucopyranoside", Carbohy. Res., 136: 207-213 (1985).
Garegg, P. J., et al., "Synthesis of 6- and 6'-deoxy derivatives of methyl 4-O-α-D-galactopyranosyl-β-D-galactopyranoside for studies of inhibition of pyelonephritogenic fimbriated E. coli adhesion to urinary epithelium-cell surfaces", Carbohy. Res., 137: 270-275 (1985).
Garegg, P. J., et al., A Synthesis of 8 Methoxycarbonyloct 1 yl O D Galactopyranosyl (1 3) O D Galactopyranosyl (1 4) 2 Acetamido 2 Deoxy D Glucopyranoside , Carbohy. Res., 136: 207 213 (1985). *
Garegg, P. J., et al., Synthesis of 6 and 6 deoxy derivatives of methyl 4 O D galactopyranosyl D galactopyranoside for studies of inhibition of pyelonephritogenic fimbriated E. coli adhesion to urinary epithelium cell surfaces , Carbohy. Res., 137: 270 275 (1985). *
Heerze, et al., "Oligosaccharide sequences attached to an inert support (SYNSORB) as a potential therapy for antibiotic associated diarrhea and pseudomonous colitis," J. Infect. Dis. 169: 1291-1296, Jun. 1994.
Heerze, et al., Oligosaccharide sequences attached to an inert support (SYNSORB) as a potential therapy for antibiotic associated diarrhea and pseudomonous colitis, J. Infect. Dis. 169: 1291 1296, Jun. 1994. *
Heerze, et al., Utilization of oligosaccharide sequences attached to an inert support (SYNSORB) as a potential therapy for antibiotic associated diarrhea and pseudomonous colitis, Abs. Gen. Soc. Micro. 46: Abs 120965, 25 May 1994. *
International Search Report mailed on Jun. 30, 1995 in connection with counterpart PCT International Application No. PCT/CA95/00060. *
Jacquinet, J. C., et al., "Synthesis of Blood-group Substances, Part 11. Synthesis of the Trisaccharide O-α-D-Galactopyranosyl-(1→3)-O-β-D-galactopyranosyl-(1.fwdarw.4)-2-acetamido-2-deoxy-D-glucopyranose", J. C. S. Perkin, 1: 326-330 (1981).
Jacquinet, J. C., et al., Synthesis of Blood group Substances, Part 11. Synthesis of the Trisaccharide O D Galactopyranosyl (1 3) O D galactopyranosyl (1 4) 2 acetamido 2 deoxy D glucopyranose , J. C. S. Perkin, 1: 326 330 (1981). *
Kameyama, A., et al., "Total synthesis of sialyl Lewis X", Carbohydrate Res., 209: c1-c4 (1991).
Kameyama, A., et al., Total synthesis of sialyl Lewis X , Carbohydrate Res., 209: c1 c4 (1991). *
Kamiya, S, et al., "Analysis of purity of Clostridium difficile toxin A derived by affinity chromatography on immobilized bovine thyroglobulin", FEMS Microbiol. Lett., 56:331-6 (1988).
Kamiya, S, et al., Analysis of purity of Clostridium difficile toxin A derived by affinity chromatography on immobilized bovine thyroglobulin , FEMS Microbiol. Lett., 56:331 6 (1988). *
Keighley, M R B, "Antibiotic-associated pseudomembranous colitis: pathogenesis and management", Drugs, 20:449-56 (1980).
Keighley, M R B, Antibiotic associated pseudomembranous colitis: pathogenesis and management , Drugs, 20:449 56 (1980). *
Kirvan, H. C., et al., "Purification of Clostridium difficile toxin A by affinity chromatography on immobilized bovine thyroglobulin", Infect. Immun., 55:1873-7 (1987).
Kirvan, H. C., et al., Purification of Clostridium difficile toxin A by affinity chromatography on immobilized bovine thyroglobulin , Infect. Immun., 55:1873 7 (1987). *
Koike, K., et al., "Total Synthesis of Globotriaosyl-E and Z-Ceramides and Isoglobotriaosyl-E Ceramide," Carbohydr. Res., 163: 189-208 (1987).
Koike, K., et al., Total Synthesis of Globotriaosyl E and Z Ceramides and Isoglobotriaosyl E Ceramide, Carbohydr. Res., 163: 189 208 (1987). *
Krivan, H C, et al., "Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence αGal(1-3)βGal(1-4)βGIcNAc", Infect. Immun., 53:573-81 (1986).
Krivan, H C, et al., Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal(1 3) Gal(1 4) GIcNAc , Infect. Immun., 53:573 81 (1986). *
Kushnaryov, V. M., et al., "Effect of Clostridium difficile Enterotoxin A on Ultrastructure of Chinese Hamster Ovary Cells", Infection and Immunity, 57: 3914-3921 (1989).
Kushnaryov, V. M., et al., Effect of Clostridium difficile Enterotoxin A on Ultrastructure of Chinese Hamster Ovary Cells , Infection and Immunity, 57: 3914 3921 (1989). *
Lee, R. T., et al., "Synthesis of 3-(2-Aminoethylthio) PropylGlycosides", Carbohydrate Research, 37: 193-201 (1974).
Lee, R. T., et al., Synthesis of 3 (2 Aminoethylthio) PropylGlycosides , Carbohydrate Research, 37: 193 201 (1974). *
Lemieux, R U, et al., "The properties of a `synthetic` antigen related to the blood-group Lewis A", J. Am. Chem. Soc., 97:4076-83 (1975).
Lemieux, R U, et al., The properties of a synthetic antigen related to the blood group Lewis A , J. Am. Chem. Soc., 97:4076 83 (1975). *
Lyerly, D M, "Epidemiology of Clostridium difficile disease", Clin. Microbiol. News 15:49-53 (1993).
Lyerly, D M, Epidemiology of Clostridium difficile disease , Clin. Microbiol. News 15:49 53 (1993). *
Lyerly, D M, et al., "Clostridium difficile: Its Disease and Toxins", Clinical Microbiology Reviews, 1:18 (1988).
Lyerly, D M, et al., Clostridium difficile: Its Disease and Toxins , Clinical Microbiology Reviews, 1:18 (1988). *
Okamoto, K., et al., "Glycosidation of Sialic Acid," Tetrahedron, 47: 5835-5857 (1990).
Okamoto, K., et al., Glycosidation of Sialic Acid, Tetrahedron, 47: 5835 5857 (1990). *
Onderdonk, A B, et al., "Comparative effects of clindamycin and clindamycin metabolites in the hamster model for antibiotic-associated colitis", J. Antimicrob. Chem., 8:383-93 (1981).
Onderdonk, A B, et al., Comparative effects of clindamycin and clindamycin metabolites in the hamster model for antibiotic associated colitis , J. Antimicrob. Chem., 8:383 93 (1981). *
Paulsen, "Advances in Selective Chemical Syntheses of Complex Oligosaccharides", Angew. Chem. Int. Ed. Eng., 21:155-173 (1982).
Paulsen, Advances in Selective Chemical Syntheses of Complex Oligosaccharides , Angew. Chem. Int. Ed. Eng., 21:155 173 (1982). *
Paulsen, H., "Synthese von oligosaccharid-determinanten mit amid-spacer vom typ des T-antigens", Carbohydr. Res., 104:195-219 (1982).
Paulsen, H., Synthese von oligosaccharid determinanten mit amid spacer vom typ des T antigens , Carbohydr. Res., 104:195 219 (1982). *
Rana, S. S., et al., "Synthesis of Phenyl 2-Acetamido-2-Deoxy-3-O-αL-Fucopyranosyl-β-D-Glucopyranoside and Related Compounds", Carbohydrate Research, 91: 149-157 (1981).
Rana, S. S., et al., Synthesis of Phenyl 2 Acetamido 2 Deoxy 3 O L Fucopyranosyl D Glucopyranoside and Related Compounds , Carbohydrate Research, 91: 149 157 (1981). *
Schaubach, R., et al., "Tumor-Associated Antigen Synthesis of the Gal-α-(1→3)-Gal-β-(1→4)-GICNAc Epitope. A specific Determinant for Metastatic Progression?," Liebigs Ann. Chem., 607-614 (1991).
Schaubach, R., et al., Tumor Associated Antigen Synthesis of the Gal (1 3) Gal (1 4) GICNAc Epitope. A specific Determinant for Metastatic Progression , Liebigs Ann. Chem., 607 614 (1991). *
Schmidt, "New Methods for the Synthesis of Glycosides and Oligosaccharides--Are There Alternatives to the Koenigs-Knorr Method?" Angew. Chem. Int. Ed. Eng., 25:212-235 (1986).
Schmidt, New Methods for the Synthesis of Glycosides and Oligosaccharides Are There Alternatives to the Koenigs Knorr Method Angew. Chem. Int. Ed. Eng., 25:212 235 (1986). *
Sullivan, N M, et al., "Purification and characterization of toxin A and B from Clostridium difficile", Infect. Immun., 35:1032-40 (1983).
Sullivan, N M, et al., Purification and characterization of toxin A and B from Clostridium difficile , Infect. Immun., 35:1032 40 (1983). *
Tedesco, F J, "Pseudomembranous colitis: Pathogenesis and therapy", Med. Clin. North Am., 66:655-64 (1982).
Tedesco, F J, Pseudomembranous colitis: Pathogenesis and therapy , Med. Clin. North Am., 66:655 64 (1982). *
Triadfilopoulos, G, et al., "Differential effects of Clostridium difficile toxin a and b on rabbit ileum", Gastroenterology, 93:273-9 (1987).
Triadfilopoulos, G, et al., Differential effects of Clostridium difficile toxin a and b on rabbit ileum , Gastroenterology, 93:273 9 (1987). *
Tucker, K D, et al., "Toxin A of Clostridium difficile binds to carbohydrate antigens I, X, and Y", Infect. Immun., 59:73-8 (1991).
Tucker, K D, et al., Toxin A of Clostridium difficile binds to carbohydrate antigens I, X, and Y , Infect. Immun., 59:73 8 (1991). *
Von Eichel Streiber, C., et al., Clostridium difficile toxin A carries a c terminal repetitive structure homologous to the carbohydrate binding region of streptococcal glycosyltransferases , Gene, 96:107 13 (1990). *
Von Eichel-Streiber, C., et al., "Clostridium difficile toxin A carries a c-terminal repetitive structure homologous to the carbohydrate binding region of streptococcal glycosyltransferases", Gene, 96:107-13 (1990).

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955449A (en) * 1991-10-18 1999-09-21 Synsorb Biotech Inc. Diagnosis and treatment of bacterial dysentery
US8541168B1 (en) * 1995-03-10 2013-09-24 Jacob Wohlstadter Multi-array, multi-specific electrochemiluminescence testing
US5817633A (en) * 1995-06-05 1998-10-06 Synsorb Biotech, Inc. Treatment of cholera
US5811409A (en) * 1995-06-05 1998-09-22 Synsorb Biotech, Inc. Treatment of cholera
US6001819A (en) * 1995-06-07 1999-12-14 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
US6121242A (en) * 1996-06-21 2000-09-19 Synsorb Biotech, Inc. Treatment of bacterial dysentery
US5849714A (en) * 1996-06-21 1998-12-15 Synsorb Biotech Inc. Treatment of bacterial dysentery
US5846943A (en) * 1996-11-08 1998-12-08 Synsorb Biotech, Inc. Solid support matricles containing a toxin binding oligosaccharide
US6013634A (en) * 1996-11-08 2000-01-11 Synsorb Biotech, Inc. Solid support matrices containing a toxin binding oligosaccharide
WO1999001140A1 (en) * 1997-07-02 1999-01-14 Neose Technologies, Inc. Oligosaccharides for attenuating xenograft rejection and methods based thereon
US6013635A (en) * 1998-05-28 2000-01-11 Synsorb Biotech, Inc. Treatment of C. difficile toxin B associated conditions
EP1704865A2 (en) * 1998-05-28 2006-09-27 SYNSORB Biotech Inc. Treatment of C. difficile toxin B associated conditions
EP1704865A3 (en) * 1998-05-28 2006-12-06 SYNSORB Biotech Inc. Treatment of c. difficile toxin b associated conditions
US6107282A (en) * 1998-05-28 2000-08-22 Synsorb Biotech, Inc. Treatment of C. difficile toxin B associated conditions
US6358930B1 (en) 1998-05-28 2002-03-19 Synsorb Biotech Inc. Treatment of C. difficile toxin B associated conditions
WO1999061031A1 (en) * 1998-05-28 1999-12-02 Synsorb Biotech, Inc. Treatment of c. difficile toxin b associated conditions
US6465435B1 (en) * 1998-05-28 2002-10-15 Synsorb Biotech, Inc. Treatment of C. difficile toxin B associated conditions
US20060029568A1 (en) * 1999-05-13 2006-02-09 Genzyme Corporation Anionic polymers as toxin binders and antibacterial agents
US6270755B1 (en) 1999-05-13 2001-08-07 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders
US20030138397A1 (en) * 1999-05-13 2003-07-24 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders and antibacterial agents
US6890523B2 (en) 1999-05-13 2005-05-10 Genzyme Corporation Anionic polymers as toxin binders and antibacterial agents
US6517827B1 (en) * 1999-05-13 2003-02-11 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders and antibacterial agent
US7678369B2 (en) 1999-05-13 2010-03-16 Genzyme Corporation Anionic polymers as toxin binders and antibacterial agents
US6517826B1 (en) 1999-05-13 2003-02-11 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders and antibacterial agents
US6290946B1 (en) 1999-05-13 2001-09-18 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders and antibacterial agents
US6419914B2 (en) 1999-05-13 2002-07-16 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders
US6730295B2 (en) 2000-05-02 2004-05-04 Genzyme Corporation Anionic polymers as species specific antibacterial agents
US6596707B2 (en) * 2001-05-24 2003-07-22 Abbott Laboratories Monovalent saccharides and uses thereof
US20090175818A1 (en) * 2002-07-22 2009-07-09 Caroline Bacon-Kurtz Poly(Potassium and Sodium Styrene Sulfonate) Its Manufacture and Its Uses
US20070053865A1 (en) * 2002-07-22 2007-03-08 Toni Chancellor-Adams Poly(potassium and sodium styrene sulfonate) its manufacture and its uses
US20070184120A1 (en) * 2003-10-01 2007-08-09 Clemson University Adhesin-specific nanoparticles and process for using same
US7682631B2 (en) 2003-10-01 2010-03-23 Clemson University Adhesin-specific nanoparticles and process for using same
US20060099169A1 (en) * 2004-10-13 2006-05-11 Ilypsa, Inc. Toxin binding compositions
US20060078534A1 (en) * 2004-10-13 2006-04-13 Dominique Charmot Toxin binding compositions
WO2006122835A1 (en) * 2005-05-18 2006-11-23 Da Volterra Colonic delivery of adsorbents
US20090324568A1 (en) * 2005-05-18 2009-12-31 Helene-Celine Huguet Colonic Delivery of Adsorbents
US8106000B2 (en) 2005-05-18 2012-01-31 Da Volterra Colonic delivery of adsorbents
US20080031867A1 (en) * 2006-05-17 2008-02-07 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
WO2007132022A3 (en) * 2006-05-17 2008-01-10 Da Volterra Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
US8388984B2 (en) 2006-05-17 2013-03-05 Da Volterra Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
WO2007132022A2 (en) * 2006-05-17 2007-11-22 Da Volterra Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
US20080089942A1 (en) * 2006-08-17 2008-04-17 Xavier Frapaise Use of adsorbent carbon microspheres to treat intestinal bacterial infections
US9132142B2 (en) 2007-09-07 2015-09-15 The General Hospital Corporation Use of secretor, Lewis and sialyl antigen levels in clinical samples as predictors of risk for disease
US9132143B2 (en) 2007-09-07 2015-09-15 The General Hospital Corporation Use of secretor, lewis and sialyl antigen levels in clinical samples as predictors of risk for disease
US9034847B2 (en) * 2009-07-06 2015-05-19 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
US20120202753A1 (en) * 2009-07-06 2012-08-09 Children's Hospital Medical Center D/B/A Cincinnati Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
US10098903B2 (en) 2009-07-06 2018-10-16 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
US11058697B2 (en) 2009-07-06 2021-07-13 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
US11324765B2 (en) 2009-07-06 2022-05-10 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
US12171773B2 (en) 2009-07-06 2024-12-24 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
US10626460B2 (en) 2013-02-21 2020-04-21 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
US10857167B2 (en) 2015-04-28 2020-12-08 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain

Also Published As

Publication number Publication date
NZ279180A (en) 1997-10-24
ZA95630B (en) 1995-10-05
AU1572795A (en) 1995-08-29
IL112428A0 (en) 1995-03-30
ATE267614T1 (en) 2004-06-15
DE69533084T2 (en) 2005-06-09
MX197129B (en) 2000-06-23
DE69533084D1 (en) 2004-07-01
KR970701064A (en) 1997-03-17
IL112428A (en) 1999-08-17
CN1140415A (en) 1997-01-15
EP0744959B1 (en) 2004-05-26
WO1995021628A1 (en) 1995-08-17
NO963378L (en) 1996-08-13
CA2181359C (en) 2001-07-03
JP4122052B2 (en) 2008-07-23
NO963378D0 (en) 1996-08-13
CN1131070C (en) 2003-12-17
US5635606A (en) 1997-06-03
CA2181359A1 (en) 1995-08-17
JPH09508631A (en) 1997-09-02
EP0744959A1 (en) 1996-12-04
AU698275B2 (en) 1998-10-29
MX9603403A (en) 1998-10-31

Similar Documents

Publication Publication Date Title
US5484773A (en) Treatment of antibiotic associated diarrhea
US6013635A (en) Treatment of C. difficile toxin B associated conditions
MXPA96003403A (en) Treatment of diarrhea associated with antibioti
AU705012B2 (en) Treatment of traveller's diarrhea
US5627163A (en) Treatment of traveller's diarrhea
US6358930B1 (en) Treatment of C. difficile toxin B associated conditions
US5811409A (en) Treatment of cholera
US6069137A (en) Treatment of traveller's diarrhea
AU704203B2 (en) Treatment of cholera
US5891860A (en) Treatment of traveller's diarrhea
US5939397A (en) Treatment of cholera
NZ332531A (en) Oligosaccharide-peptide conjugate and use in treating cholera

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALBERTA RESEARCH COUNCIL, CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HEERZE, LOUIS D.;ARMSTRONG, GLEN D.;REEL/FRAME:006940/0634

Effective date: 19940318

AS Assignment

Owner name: SYNSORB BIOTECH INC., CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALBERTA RESEARCH COUNCIL;REEL/FRAME:007663/0435

Effective date: 19950915

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: GATX/MM VENTURE FINANCE PARTNERSHIP, CANADA

Free format text: SECURITY INTEREST;ASSIGNOR:SYNSORB BIOTECH, INC.;REEL/FRAME:009798/0908

Effective date: 19981222

FPAY Fee payment

Year of fee payment: 4

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: ILYPSA, INC., CALIFORNIA

Free format text: CONFIRMATORY PATENT ASSIGNMENT AGREEMENT;ASSIGNOR:ITERATION ENERGY, LTD.;REEL/FRAME:018951/0237

Effective date: 20061206

FPAY Fee payment

Year of fee payment: 12